Statistical efficiency of survival endpoints in breast cancer clinical trials by Ferrer Playan, Jordi
MSc in Statistics and 
Operations Research 
 
Title: Statistical Efficiency of Survival Endpoints in Breast Cancer 
Clinical Trials 
 
Author: Jordi Ferrer Playán 
 
Advisor: Guadalupe Gómez Melis 
 
Co-advisor: Urania Dafni 
 
Department: Statistics and Operations Research 
 
Academic year: 2011/2012 
Master’s Degree Thesis      MSc in Statistics and Operations Research 
 2 
Master’s Degree Thesis      MSc in Statistics and Operations Research 
 3 
Statistical Efficiency of Survival Endpoints 













JORDI FERRER PLAYÁN 
 
Main Advisor:  
GUADALUPE GÓMEZ MELIS 
Department of Statistics and Operations Research 




Professor of Biostatistics and Director of the Laboratory of Biostatistics 
Faculty of Nursing. School of Health Sciences. University of Athens 
 
Master’s Degree Thesis      MSc in Statistics and Operations Research 
 4 




I would like to thank Professor Lupe Gómez, this Master’s Thesis director, for her dedication 
and support, her thorough reviews and her valuable feedback; and also for introducing me to 
the fascinating world of the survival analysis. 
I would like to thank also Professor Urania Dafni for her support and comments throughout 
the duration of this Master Thesis. 
And finally I would like to thanks Moisés Gómez from the Universitat Politècnica de Catalunya 





Master’s Degree Thesis      MSc in Statistics and Operations Research 
 6 




The drug development and marketing process is long and runs through different phases where 
the tested drugs must show how effective and how safe they are. This process may last up to 
12 years, and only a very low percentage of the drugs that start the first phases of 
development succeed and reaches the market. 
Time is not the only concern. The investment in development programs is significant, not only 
to cover the expenses of an R&D department dedicated to monitor and survey the clinical 
development, but also to cover those drugs that are stuck on its way to the market. Increasing 
the efficiency in our development process is key, thus, to optimize the pharmaceutical industry 
investment in this savings and cuts era. 
This work contributes to this end and is based on Gomez and Lagakos paper
1
, which has been 
recently accepted in the Statistics in Medicine journal. This paper describes a methodology 
based on the Asymptotic Relative Efficiency (ARE) to test efficiencies of clinical trial endpoints 
in survival analysis, and allow the investigator to choose among single endpoints such as death 
or progression, or composite endpoints such as progression-free survival, which includes death 
and progression as we will explain further, provided certain information that shall be obtained 
from investigators. 
We focus on breast cancer data, although the methodology could be broadly applied to 
survival data. Through a bibliographic research of breast cancer clinical trials papers, that 
allowed us working with data as realistic as possible, this work runs several ARE calculations 
and pretends to identify trends and potential guidelines for investigator and pharmaceutical 
industry on the use of the most efficient clinical trial endpoint in each scenario given certain 
conditions, and how potentially this may derive in sample size reductions. 
We have studied the behavior of the ARE in each case based on real data coming from 
published papers. 
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“I will also ask for an appropriation of an extra $100 million to launch an intensive 
campaign to find a cure for cancer, and I will ask later for whatever additional funds can 
effectively be used. The time has come in America when the same kind of concentrated 
effort that split the atom and took man to the moon should be turned toward 
conquering this dreaded disease. Let us make a total national commitment to achieve 
this goal.” 
President Richard M. Nixon, January 1971 State of the Union Address 2 
Four decades later, cancer is still the second-leading cause of death in the US, accounting for 
25% of all deaths (roughly 556,000). Worldwide, spending for drugs associated with cancer 
increased a rate of 15% per year over the last 15 years, and today it is estimated to cost 
approximately $40 billion per year, growing at record rates in the last decade driven in part by 
the cost of new medical interventions.
3-6
 
The authorities spend time, money and resources in comparative effectiveness research 
assuming that this information relative to costs and benefits will improve the decision making. 
But the actual “first-world countries” economic situation and the fact that there are currently 
more than 100 new molecules in phase III oncology trials, makes necessary to streamline the 
cancer treatment and research spending. 
One of the objectives of the scientific community objective is thus, to identify the most 
efficient treatments for oncology patients guaranteeing the best response to the treatment, 
and prolonging patient survival. 
This objective should count with the support of the pharmaceutical industry, who try to 
optimize the spending on research, that would impact at the end with the treatment cost.  
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1.2. Drug development  
 
In clinical trials, the utility of quantifying cancer outcomes is based on their potential to predict 
patient outcomes. Unfortunately, an active drug is not necessarily an efficacious drug; and the 
shrinkage or disappearance of the tumoral mass are not sufficient to obtain an increase in the 
survival or improvement in the quality of life of cancer patients. 7 
The discovery of a new drug starts at the pharmaceutical labs, with the identification of 
molecules that are active against a disease or pathology, and the posterior development with 
the in vitro and in vivo tests. But obviously this evidence does not prove the safety or the 
efficacy of new treatments, so the next step for the selected molecules is to be tested in 
clinical trials.  Small clinical trials first, called phase I and phase II trials, with few patients and 
highly monitored to avoid any unknown and undesirable patient reaction; and big ones later to 
ensure the safety and efficacy of the investigational drug, phase III and phase IV clinical trials. 
A summary of the different clinical trials phases is summarized in Table 1. 
This time consuming and expensive development process is meant to prevent disasters like the 
newborn defects caused by the Thalidomide, a drug introduced in the 1950s to treat morning 
sickness, and responsible that 10,000 children in 46 countries were born with deformities, as 
showed in figure 1. 
 
Figure 1 - 1962 born baby to a mother who had taken thalidomide while pregnant 
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Only if the results mainly from phase I to phase III trials – phase IV trials are usually post-
marketing to ensure the product is safe after authorization - are significantly positive, the 
sponsor can claim the product approval to Health Authorities approval – each country has one 
regulatory agency evaluating the data -, and then, after years of development the new product 
is supposedly granted with market access.  
This, however, does not guarantee the new drug stays for long in the market, because the 
product marketing is the “largest trial” it will undergo, reaching a far bigger amount of 
patients, and is at this time point when the side effects with lower frequency may appear. The 
ongoing control of the mentioned agencies and sponsors, and the obligation to report any 
untoward drug reaction to the health authorities, ensure that if any adverse drug reaction of a 
marketed drug unbalance the risk – benefit ratio, it is removed immediately from the market. 
 
Phase Purpose Number of people who take 
part 
To find a safe dose 
To decide how the new treatment should be given 
Phase I 
To see how the new treatment affects the human body 
15-30 people 
To determine if the new treatment has an effect on a certain cancer Phase II 
To see how the new treatment affects the human body 
Less than 100 patients 
Phase III To compare the new treatment (or new use of a treatment) with the current 
standard treatment 
From 100 to several thousand 
patients 
Phase IV To further assess the long-term safety and effectiveness of a new treatment Several hundred to several 
thousand patients 
Table 1- Clinical Trial Development Phases 
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1.3. Clinical trial objectives 
 
One of the reasons of the high cost of the oncology treatments is the cost for the 
pharmaceutical companies to develop and market a new drug.  And choosing the right clinical 
trial endpoint is the first hurdle the scientists and physicians have to overcome when designing 
a clinical trial. This question is as relevant as if the molecule they want to test is effective or 
not, and is around the answer, using what we already know from this molecule – how it 
behaves in small population groups - and what we expect to see in our target population, that 
we will define the clinical trials sample size, the trial duration and safety parameters to take 
into consideration.  
There are different types of clinical trial endpoints, based either on objective response rates, 
quality of life or survival, as we will describe later in section  1.4, but the selected endpoint 
needs to be consistent throughout the product development period - which may take several 
years -. If a product completes the phase III trials, this would mean that this new drug is the 
one between 5.000 or 10.000 that started the early development phases, and that will be 
used, if the results are favorable, to claim for the indication it has been tested for many years.  
It exists an outstanding question that will not be approached in our study, whether 
investigators should prioritize quality of life indicators rather than efficacy, as to which costs 
(side effects, long treatments) are some treatments enlarging patients’ life. Kozmininski et al 
8
, 
analyzed data from 786 surveys sent to US oncologists. In this study, the authors described 
two different scenarios where the oncologists were supposed to prioritize between survival 
prolonging or quality of life enhancing criteria to choose the patient’s treatment in each 
scenario. The results of this study were that there was a wide variation across oncologists 
when they have to choose between survival and quality of life. 
Among all clinical trial endpoints, the study we are presenting here has the objective to help 
the scientific community in the process of selection of survival endpoints. This study pretends 
to be a statistical tool to help in the early phases of the drug development, which would 
optimize the number of patients that needs to be dosed in a clinical trial, and that gives us 
guarantees that is the best one among all different survival options.  
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1.4. Clinical trial endpoints in oncology 
 
As mentioned before, the discussion on the selection of clinical trial endpoints is linked to the 
trial design, in the early phases of its development. Like any other disease, cancer can be 
approached from different points of view, offering different types of clinical trial endpoints. 
The endpoints discussed here are distributed in three groups, as described by the FDA 
Guidance for Industry of May 20079 , and include Overall Survival, Endpoints based on Tumor 
Assessment, and Endpoints Involving Symptom Assessment. 
A. Overall Survival (OS): defined as the time from patient randomization (allocation to a one 
treatment arm) until death from any cause. Is considered as the most reliable cancer 
endpoint, and is the preferred to assess patient survival because it is precise and easy to 
measure. Demonstration of statistically significant improvement in overall survival can be 
considered to be clinically significant if the toxicity profile is acceptable, and has often 
supported a new drug approval. 
B. Endpoints based on Tumor Assessments: The collection and analysis of data on these 
time-dependent endpoints are based on indirect assessments, calculations and estimates.  
1. Disease-Free Survival (DFS): time from randomization until recurrence of tumor or 
death from any cause. Frequently used in the adjuvant setting after definitive surgery 
or radiotherapy. 
2. Objective Response Rate (ORR): proportion of patients with tumor size reduction of a 
predefined amount or for a minimum time period. 
3. Progression Free Survival (PFS): time from randomization until objective tumor 
progression or death from any cause, whichever comes first.  
We may assume that PFS and DFS only differ on the disease phase, and therefore they 
are somehow equivalent. In early cancer stages, neo-adjuvant and/or surgery 
interventions may completely remove the tumoral cells, and medical doctor may 
consider the patient as “clean” or “disease-free”, whilst in advanced patients 
treatment may help only reducing the tumoral mass or slow the tumor growth, and 
therefore the endpoint tries as objectively as possible to define time until disease 
progression, i.e. worsening of cancer. 
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4. Time to Progression (TTP): time from randomization until objective tumor 
progression. TTP does not include deaths. In TTP analysis, deaths are censored, either 
at the time of death or at an earlier visit representing informative censoring (non-
random pattern of loss from the study). 
5. Time to treatment failure (TTF): time from randomization to discontinuation of 
treatment for any reason, including disease progression, treatment toxicity and death. 
TTF is not recommended by the FDA for drug approval, because does not distinguish 
the efficacy of the drug from toxicity. 
C. Endpoints involving Symptom Assessment and Biomarkers: These two last groups do not 
serve as primary efficacy endpoints in oncology drug approvals. Symptom improvement 
can simply indicate less toxicity, and further research for biomarkers needs to be done to 
establish its validity. 
The United States Food and Drug Administration (FDA) recommends meeting his specialists 
before submitting the clinical trial protocols design, to confirm the Agency accepts the design 
and the endpoint chosen to show improvement in the selected disease. 
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1.5. Choosing the best clinical trial endpoint 
 
In the early 1980s, the FDA approved oncology drugs based on tumor Response Rate alone. In 
the mid-1980s, on the advice of the Oncologic Drugs Advisory Committee (ODAC), the FDA 
determined that response rate generally should not be the sole basis for approval. The 
potential benefit associated with a partial response did not necessarily outweigh the 
substantial toxicity of oncology drugs, and the correlation between response rate and survival 
or clinical benefit was not well established. The new FDA position called for an improvement in 
survival or patient symptoms for regular approval 10. Today, and given its objectivity and the 
unquestionable benefit derived by patients, overall survival has been the most important 
endpoint in medical oncology and has been broadly recommended from health authorities and 
a survival cornerstone. 
However, overall survival has been shown to be an elusive endpoint. Although objective and 
simple to measure, it has the disadvantage of requiring long follow-up periods, increasing the 
costs and duration of these trials; may be confounded by causes of mortality unrelated to 
cancer; and the effects of a drug in overall survival may be diluted by the effects of crossover 
and subsequent therapies. And still one argument on patient wellness: prolonging the patient 
survival does not translate into an improvement on the quality of life
11
. 
Because of the number of new promising treatments arriving in phase III trials for advanced 
breast cancer, there is an urgent need to identify endpoints that are more sensitive and more 
rapidly observed than OS.  In recent years there has been an increase in the use and regulatory 
acceptance of PFS as primary endpoint in cancer clinical trials: as explained already, PFS looks 
forward to either death - as Overall Survival does - or disease progression, whichever comes 
first. A key advantage of the progression-free survival end-point is that progression occurs 
months or years before death, and therefore the time required to get the number of events 
statistically required is shorter for PFS than for OS. However, there are several points that have 
been criticized concerning the use of PFS as primary endpoint in oncology trials: 
PFS is not an entirely objective end-point – definition of progression may vary among trials -, 
and thus can be subject to bias. This is partially resolved blinding the patient and/or the 
investigators, but can still be a concern if there are differences in the toxicity of different arms, 
which may partially unblind the trial. Another concern is that it is complicate to demonstrate 
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that effect on PFS does correlate in effect to OS12; and finally, informative censoring: those 
patients that at the cut-off time for analysis are still alive or did not showed progression, shall 
be balanced in both groups. 
This type of endpoints - such as PFS or TTF - are known as composite endpoints (CE), and are 
defined as the occurrence of any event among a given set of events after a certain follow up 
time. A patient that experiences any of the CE events (components) will be considered to have 
experienced the event of interest.  In the PFS case, it means that a patient that experiences 
either disease relapse or death is counted as if he has experienced the event. In other words, 
we are adding disease progression to the overall survival. 
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1.6. Composite endpoints 
 
CE are defined thus as the occurrence of any event from among a set events after a certain 
time of follow-up. This allows adopting several endpoints as a single one. 
Its use was approved and described in the International Conference for Harmonization (ICH) of 
Technical requirements for Registration of Pharmaceuticals for Human Use – Efficacy 
Guidelines part 9 – , finalized on February 199813 as follows: 
“If a single primary variable cannot be selected from multiple measurements associated 
with the primary objective, another useful strategy is to integrate or combine the 
multiple measurements into a single or 'composite' variable, using a pre-defined 
algorithm (...). This approach addresses the multiplicity problem without requiring 
adjustment to the type I error.” 
It is also recommended in these guidelines that its use shall be transparent. The construct of 
this composite endpoint shall be pre-specified in the protocol; the sample size shall be 
calculated taking into account the overall number of events of all endpoint components, and 
any statistical significant result is attributed to the CE, and not to any of its component, unless 
it is clinically meaningful and has been validated. This prevents of investigators constructing 
the composite endpoints based on ongoing trial results.  
At first glance it may seem that using composite endpoints would make easier the 
investigator’s job, as man can add any endpoint of interest without the need of adjusting for 
multiplicity, but this may be not always the case. The main purpose of composite endpoints is 
to include as many clinically relevant endpoints as possible in the efficacy assessment of a 
treatment without having to increase the sample size to an unacceptable level14. 
Ferreira-González et al15, performed a systematic review of the literature looking for controlled 
clinical trials were investigators considered using composite endpoints.  Among the selected 
trials, they summarized the rational, the interpretation, the advantages, limitations and 
recommendations. The main advantage they came up with was that investigators used 
composite endpoints because it increases the statistical power when assessing intervention 
differences, and therefore allows a lower sample size. This may be translated in money 
savings, reduction of follow-up time, and more ethically accepted, understanding that less 
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number of patients will be recruited on a clinical trial. Some authors highlighted, however, that 
if treatment effect is not similar across all of the components, and as consequence, the global 
risk reduction for the composite is reduced, the required sample size may increase. 
Freemantle et al16 put the example on his paper of the CAPRICORN trial17, trial investigated the 
effects of carvedilol, a β-blocker, in 1959 patients with left ventricular dysfunction following 
myocardial infarction. The primary endpoint stated in the protocol was all-cause death, but 
while the study was ongoing, the data and safety monitoring board, which has the key role of 
protecting the interest of patients
18
, communicated to the investigator’s steering committee 
(SC) that the overall rate of accrual of death was lower than predicted. This lower number of 
death was threatening the statistical power to detect differences. The SC took the decision of 
modifying the primary endpoint and turned it into a composite endpoint (all-cause mortality or 
cardiovascular hospital admissions). The original primary endpoint achieved a p-value of 0.03, 
whereas the alternative primary endpoint had a p-value of 0.30. Thus, the trial did not met the 
primary endpoint so could not demonstrate the benefits of carvedilol in those patients. This 
example demonstrates the consequences of using a composite endpoint, where one 
component may dilute the measure of treatment effect of other components that may show 
evidence of efficacy, and highlights the importance of carefully choosing the components of 
CE. 
On the other hand, back to Ferreira-González’s paper, the most widely considered 
disadvantage of composite endpoints is the fact that all components are considered as 
equivalent in the analysis, irrespective of its relevance for patients. It could be particularly 
misleading if an overall effect is driven by a less important component of the endpoint. A 
substantive risk associated with the reporting of composite outcomes is that the benefits 
described may be presumed to relate to all of the components. Likewise, the results 
interpretation may be problematic if the magnitude of the effect is very dissimilar on each of 
the components, reaching its maximum if any of the components shows opposite directions. 
We could easily conclude that by adding new clinical outcomes it may increase the probability 
to detect these events, and reduce time, costs and resources. Unfortunately this assumption is 
not correct. Before adding such an added endpoint, some questions should be addressed: 
• Is this new event clinically relevant? In other words, does the addition of this extra 
event provide an added value? 
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• May this new event be as frequent in the control group as in the group we are 
investigating, which may mask our treatment effect? 
• Are we able to develop a statistical method that may help us taking this decision 
We will try with this paper to answer the last question.  
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1.7. Breast cancer 
 
It is not realistic today treating all cancers as a single and same disease, because we know 
there are many types of cancer: 
• Carcinoma - cancer that begins in the skin or in tissues that line or cover internal 
organs. 
• Sarcoma - cancer that begins in bone, cartilage, fat, muscle, blood vessels, or other 
connective or supportive tissue. 
• Leukemia - cancer that starts in blood-forming tissue such as the bone marrow and 
causes large numbers of abnormal blood cells to be produced and enter the blood. 
• Lymphoma and myeloma - cancers that begin in the cells of the immune system. 
• Central nervous system cancers - cancers that begin in the tissues of the brain and 
spinal cord 
To reduce any potential source of bias, and with data as comparable as possible, this study will 
focus on one single type of cancer disease. Among all different types, and seen the differences 
on incidence, detection methods, number of treatment lines and prognostic, this study 
focused on breast cancer patients because of the following figures. According to the last 
information available (June 2011): 
• There are 370,000 new cases per year diagnosed in Europe. 
• The incidence in North European countries is 82.5 /100,000 inhabitants / year; while in 
Sothern European countries the rate is 62.4 / 100,000 inhabitants / year. 
• In Spain, there are about 22,000 new cases per year which represents almost a 30% of 
all cancers. 
• In Catalunya there are 83.9 cases /100,000 inhabitants, while the national mean is 50.9 
cases / 100,000 inhabitants. (last update from June 2011)  
• And with regards to mortality, in 2004 the number of breast cancer deaths in 




Beyond Europe, breast cancer is an also an actual concern in the United States: 
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• In 2011, an estimated of 230,480 (female) and 2,140 (male) new cases of invasive 
breast cancer were expected to be diagnosed in women in the US, along with 57,650 
new cases of non-invasive (in situ) breast cancer.  
• These will cause 39,520 female and 450 male deaths. 
• About 12% of US Women will develop invasive breast cancer over the course of her 
lifetime. 
• Breast cancer is, together with lung cancer, the two diseases that kill more women 
than any other disease in the US
20
 . 
Unfortunately, there has not been any revolution neither in the diagnose or in the treatment 
of breast cancer, which may mean that these figures will be similar ones to what registries will 
show from 2011 and will be in 2012. 
It’s worthwhile then to look into this disease and see how statistics can we contribute to 
optimize the clinical trial endpoint in new therapies being investigated. 
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1.8. Progression free survival as surrogate for overall survival 
 
As discussed in section 1.6, how to validate the “true” endpoints has caused considerable 
controversy in the past decades. There are many discussions and studies trying to defend the 
use of PFS as a surrogate endpoint of OS, but showing correlation between both endpoints 
does not make a surrogate. PFS needs validation and must reasonably likely to predict clinical 
benefit.  
Several authors tried to show with examples how OS was not the most appropriate endpoint21-
22-23 in different indications such as colorectal or breast cancer, highlighting clinical trials’ 
results that did not show statistical differences on the OS when this was the primary endpoint, 
but when this data was analyzed through meta-analysis, some of these trials showed that 
there were statistical differences on other endpoints such as progression or objective response 
rate. Although the surrogacy of OS has not been firmly established in breast cancer, PFS has 
been chosen as the primary endpoint in the majority of recent trials as the basis for approval 
as we will see as we advance in our study. 
From 1990 until 2002 there was a single FDA approval relying primarily on Time to Progression 
or Progression Free Survival without also relying on a survival benefit. But, over the past seven 




If we look into the PFS or DFS definition, we see that we are able to split these outcomes into 
two different ones. For instance, with PFS we are creating a single endpoint made of disease 
progression and death. This means that we are observing those patients that may have been 
considered as well if we would take care only of deaths (OS), but we are adding here 
progression, and thus patients that may be alive at the end of the trial, but that showed 
disease progression during the course of the trial. Therefore, we increase the probability to see 
events in our clinical trials.  
Graphically, to describe all potential scenarios one can find when trying to identify surrogate 
endpoints to OS, we summarized them all on Figure 1: 
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Figure 2: survival scenarios 
Since FDA guidelines recommend the use of overall survival as a survival endpoint, and to ease 
future explanations, we have named death as E1 (event 1) and will be our event of interest; 
and E2 the alternative event (ie. progression, treatment failure…). T1 is the time from 
randomization - time when we allocate the patient to one of the treatment arms - to reach our 
event of interest (death); and T2 the time to reach the alternate endpoint. Logically, If both E1 
and E2 are observed, T2 will always be inferior to T1, because “death prevents us to see the 
progression” (T2 < T1). In other words, E1 is a terminating event.  
According to this, we may be able to observe 4 different scenarios: 
• Patient #1: a patient randomized at T0 (allocated to one treatment arm), and that 
experienced E2 only (progression), but not death at the time of the end of the study. 
From this patient we are able to get T2 only.  
• Patient #2: patient randomized at T0 that presents E2 (progression), and E1 
afterwards, so we can get T2 and T1 information.  
• Patient #3: patient that shows E1 only, so we will only get T1. 
• Patient #4: is a patient that after the treatment and throughout the trial does not 






ε2: progression  (T2 : time to progression) 
ε1: death  (T1 : time to death) 
EOS: end of study (TEOS : time to EOS) 
1 
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As described in section 1.6, a key advantage of a composite endpoint is that it allows 
investigators who are having difficulty deciding on a single endpoint combining two or more 
outcomes that describe a disease process. In our case, we consider Death as the main event – 
we will call it relevant endpoint – and the one we expect to observe in our clinical trial. And we 
introduce Disease Progression as an additional endpoint, which we think it may reduce the 
time of patient follow up, and thus shorten our timelines.  
As said above, progression may be observed much before death.  We will call this composite 
endpoint E*, and will be defined as: 
E*= E1 U E2 
And the time (T*) to this composite endpoint will be the minimum between progression and 
death. 
T* = min {T2, T1}; 
Note that, as we deduced from Figure 2: survival scenarios, E* will only be observed if any of 
the events happens before the EOS, ie:  
T* < EOS 
By adding a new endpoint we are increasing the probability of detecting an event in our 
patients. If we consider α as the probability of finding each patient group in our population, we 
can state that: 
P1 = α2 + α3 
P2
 
= α1 + α2 
P*= α1 + α2 + α3; 
where P1 is the probability of observing death, P2 probability of observing progression and P* 
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2. Objective of this master’s thesis  
 
As described in the introduction, overall survival (OS) is the authorities’ preferred clinical trial 
endpoint in oncology trials, given its objectivity and that it is easy to measure. However, it may 
require in some cases long time to get the required number of events to perform the statistical 
analysis of OS, which impacts directly to the final cost of the product. Furthermore, increasing 
patient’s life is not the only objective of the scientific community, but also increasing patient’s 
quality of their remaining life, i.e. for instance reducing or delaying the patient’s progression 
rate. By measuring only the overall patient’s survival it is not possible to have any clue of 
patient’s quality of live during the clinical trial. Time to progression may provide us broader 
information on patient’s status during the trial period. 
The current situation is thus, that the investigators’ community and the economic situation 
require the acceptance of other clinical endpoints which would be able to shorten the clinical 
trial duration, thus clinical development costs, and create endpoints that may reflect patient’s 
quality of live. These might be the so called composite endpoints.  
Since the objective of composite endpoints is to increase the efficiency of the clinical trials, the 
purpose of this study will be to evaluate in which cases the use of single endpoints (overall 
survival) will be more statistically efficient to detect differences in clinical trials, and in which 
ones the addition of a second endpoint (progression), building a composite endpoint, will be 
beneficial to show differences between the treatment groups.  
This study is based on breast cancer clinical trials, for the reasons given at section  1.7, and the 
information has been obtained from a bibliographic review of breast cancer clinical trials 
published between 2009 and 2010 as will be described in section  4. It was limited to those two 
years to try to obtain data as homogenous as possible, and to limit the bias that might have 
caused changes on the standard of care of breast cancer disease. 
Among other composite endpoints, we will analyze those that are based on survival outcomes. 
Namely, we extracted information from trials that used single endpoints such as Overall 
Survival or Time to Progression, and information from trials that used composite endpoints 
such as Disease-free survival or Progression-free survival. 
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The statistical methodology that will be used to analyze this data is based on the asymptotic 
relative efficiency (ARE), as defined in Gomez and Lagakos1 paper, that will be better described 
on the following sections. Through the calculation of the ARE, we pretend to be able to decide, 
having defined a baseline conditions of what an investigator expects to observe in terms of 
hazard ratio, probability of observing and event, and some statistical parameters that will be 
later introduced, when the use of OS would be more efficient to detect statistical differences 
between two treatment arms, and when, by adding the detection of progression we increase 
the efficiency of clinical trials. 
A subsequent objective of this study would be, and due to the fact that the same information 
than the one needed to calculate the ARE, is used to calculate the clinical trial sample size, we 
may be able to use the information obtained to calculate the clinical trial sample size with the 
less number of patients treated as possible maintaining the desired power (1-β) and level of 
significance (α).  
In summary, increasing the efficiency of clinical trials designs is not only a benefit from an 
economic point of view because it optimizes the trial duration; but also from an ethical point 
of view, we may be able to statistically reduce the number of patients to be recruited in a 
clinical trial, and therefore expose less patients to investigational research. 




3.1. Statistical methodology 
 
The methodology described in this thesis is based on the paper “Statistical considerations 
when using a composite endpoint for comparing treatment groups” developed by Guadalupe 
Gómez and Stephen Lagakos 
1
.  
The above paper developed a statistical methodology for deciding whether to expand a 
primary endpoint (E1) to the composite (E*=E1 U E2), by means of the Asymptotic Relative 
Efficiency of two logrank tests. 
The mentioned paper describes 4 different scenarios, depending on the type of endpoints 
selected for comparison: 
• Case 1: none of the endpoints include a terminating event. In this case both E1 and E2 
are observed if they occur before the end of the study (EOS), i.e.: T1 < EOS and T2 < 
EOS. 
• Case 2: the endpoint of interest (E1) does not include a terminating endpoint but the 
additional (E2) does. In such case E1 can only be observed if it occurs before the 
additional endpoint E2, T1 < min {T2, C} while T2 < EOS. 
• Case 3 (the case we will consider): the endpoint of interest is a terminating endpoint 
and the additional one does not. In this case E1 is observed while it happens within the 
study time (T1 < EOS), while E2 can only be observed if it occurs before the endpoint of 
interest E1 or the end of the study, T2 < min {T1, C}. 
• Case 4: Both events include a terminating event, meaning that each event would be 
observed if T1 < min{T2, C} and T2 < min{T1, C}. 
These scenarios can be graphically described as showed in Figure 3. 
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Figure 3 - Graphical distribution of case scenarios described in Gomez and Lagakos paper 
In our case, seen that overall survival is the Health Authorities’ preferred endpoint, we will set 
death as our relevant endpoint (E1). It is a terminating endpoint which prevents us to observe 
any other posterior endpoint, so we will base our study in the case 3 scenario: death will be 
our event of interest, and we will explore if by adding progression and creating a composite 
endpoint the results improve. 
Therefore Progression will be our additional endpoint (E2), which is a non-terminating event 
that may allow us to observe death after it. 
1. Since E1 is a terminating event, T1 will be observed as long as it occurs before the EOS; 
T1 < EOS; 
2. And T2 will only be observed if occurs before T1 and EOS 
T2 < min {T1, EOS} 
3. The observed endpoint will be denoted U = min {T1, EOS }, while for the composite 
endpoint, T* will be observed if it occurs before the EOS, i.e. T* < EOS and we will 
name the outcome observed as U* = min {T*,EOS}  
Apart from this notation, this procedure has as well some assumptions, based on the 
experience of previous clinical trials.  Efficiency calculations will be evaluated through a 
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I. Assumption 1: End-of-study censoring at time τ (without loss of generality we take τ = 1) 
is the only non-informative censoring cause, that is,  
Pr {EOS > t} = 1{[0, τ]} (t) = 1{[0; 1]}(t) 
Declaring that EOS is the only non-informative censoring, we are stating that a patient 
that completes the clinical trial follow-up period and is still alive, has the same risk of 
death than a patient that is still ongoing, and we do not have any added information on 
this patient future survival. Hence, any other censored data: i.e.: discontinuation from 
clinical trial due to toxicity, will be considered informative. 
It is important to highlight that these assumptions are not only important and significant 
from a statistical point of view.  
Non-informative censoring prevents us from getting information from the recruited 
patients. When the sample size calculation is performed at the set up phases of a clinical 
trial, most often what it is calculated is the number of events needed to show statistical 
differences between treatment arms. From this number of events, investigators assume 
a number of patients from which they will not be able to observe the event, and 
therefore the real sample size that will be recruited. 
In clinical trials, sometimes we have the risk to have patients who are lost to follow-up, 
especially in those trials where the follow-up period is long (may be of several years). If a 
patient changes his/her residence during the trial duration and is not able to attend the 
appointments scheduled along the trial duration, this prevents us to get the information 
from the patient, and are forced to censor the patient unless the reason for 
discontinuation is related to the trial endpoints, this censoring is non-informative. If 
there is no informative censoring other than the EOS, we may be at risk of having 
underestimated the number of patients needed, and therefore being unpowered to 
make any statistical assessment. 
We will discuss further on this issue in the limitations section of this study. 
II. Assumption 2: End-of-study censoring is identical across groups, that is, Pr {EOS > t | X = 
0} = Pr {EOS > t | X = 1} = Pr {EOS > t} = 1{[0, τ]}(t). This assumption facilitates 
computations and derivations although the general expressions could be analogously 
stated without it. 
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Statistical considerations aside, and since the purpose of the clinical trials in our study is 
to compare survival data, at the eyes of the authorities it would not be acceptable to 
have different follow up times depending on the treatment arm a patient is allocated to. 
Nowadays some clinical trials are blinded, and those which are not define very well in 
the protocol that the follow up time is independent of the treatment assigned to the 
patient. To provide evidence of improvement, both treatment groups have the same 
follow up time. All clinical trials considered in this study are randomized clinical trials, so 
what has been observed throughout the study is that most of the clinical trials designs 
have the same trial duration, and the treatment is randomly assigned to a patient. This 
means that is at the baseline visit (time of randomization), the patient is allocated to a 
treatment arm, but the trial duration or the follow up is independent to the treatment 
arm the patient has been assigned.  
III. Assumption 3: Treatment groups have proportional hazards. The risk of an event in one 
group relative to the other does not change with time. This is a key assumption and 




























= : hazard ration of the additional endpoint, progression in our case, 
for all t. 
It is important to mention that all trials where the method to calculate the hazard ratios 
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3.2. Logrank test 
 
In survival analysis, we often want to compare different treatment effects on two (or more) 
patient groups. Experiments in which observations are the time to occurrence of an event are 
common source of right-censored data. In these cases, what we would like to know is the 
incidence of the event over time25.  
Considering that in our trials patients have been allocated to one of two treatment arms, when 
we compare survival data we establish: 
(.)(.): 210 SSH =  , or similarly (.)(.): 210 λλ =H , 
where S1 and S2 are the survival functions of T1 for group 1 and 2, and 1λ  and 2λ  are the 
hazard functions for each group. 
The most widely used method to compare two survival curves is the Logrank test, a 
nonparametric test appropriate to use when the data is censored. The null hypothesis of the 
logrank test is that there’s no difference on between the populations in the probability of an 
event at any time point26. Under this null hypothesis, the logrank test is asymptotically N(0,1).  
To calculate the logrank test we need to sort chronologically the combined events observed 
from two treatment groups, as if we had only one group. At each time point where we have an 
event, say one patient that progressed, we calculate the number of patients that are still alive 
in each group and calculate the probability that the observed event belongs to that treatment 
group. 
It is important to highlight that patients who are censored are not considered as an event in 
this method; it only contributes with a reduction of patients at risk at the time of the following 
event. This information is collected during all trial duration, so that at the end of the trial we 
will know the total number of patients that we expected from each treatment arm for which 
we expected to observe an event. 
The data can be summarized in a 2x2 table. In a two arms trial, where we want to observe the 
event d (death for example), we could summarize our data at a given time point (ti) as: 
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Arm Events Survivors Total at risk 
1 di1 Ri1 - di1 Ri1 
2 di2 Ri2 - di2 Ri2 
Total dij Ri - di Ri 
 
where dij is the number of deaths from group j at a time ti, treatments are T= j (1,2); Ri is the 







as an estimator of )(1 itλ . 
Under the null hypothesis, the hazard functions are equal in both treatment groups over time, 
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holds a χ2 with one degree of freedom and rejects the null hypothesis for extreme values of di1. 
Generally, in our survival curves, we will be interested to test that this null hypothesis holds at 























































where Oi is the number of events observed at time ti, and Ei is the expected number of events 
to be observed at time ti. 
Under the H0 of no treatment differences, the logrank test is asymptotically N(0,1), but when 
the H0 does not hold, and if we consider a sequence of contiguous alternatives to H0, for a 
finite sample size (n), and  considering 1λ as fixed and 2λ  vary with n, the log rank Z results to 
be asymptotically normal with unit variance and mean μ. 
This centrality parameter (μ) is function of { }iUXip H ≥== |1Pr)( 0 ; the null probability that 
someone at risk at time ti, is in treatment 1, { }iUH ≥0Pr is the null probability that someone is 
still at risk at time ti, and )(}{Pr 10 itUH λ≥ is the probability under H0 of observing E1 by time t. 
Likewise, and as introduced above, we called T2 the time to the secondary endpoint E2, and T* 
= min{T1,T2} to the composite endpoint. Likewise, to test the null hypothesis of no treatment 




0 λλ =H , we can use the logrank test. Under the H0, Z* is 
asymptotically N(0,1), and when the null hypothesis does not hold, Z* is asymptotically normal 
with unit variance and mean μ*, that is function of { }iUXip H ≥== *0* |1Pr)( : the null 
probability that someone at risk at time ti, is in treatment 1, and { }tUH ≥**0Pr : the probability 
under H0 that someone is still at risk at time ti. 
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Function survdiff from the library survival in R27, runs through a given file where it has been 
previously indicated the treatment arm, the times where the events occurred, and the 
existence of censoring. The parameter rho = 0 corresponds to the logrank method, and the 
output of this method provides information on the statistical differences between survival 
curves. 
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3.3. Asymptotic relative efficiency 
 
One way to compare two statistical tests is to compare their efficiencies. In our study, we will 
check the differences between using the test Z, based on E1 (relevant endpoint), and using the 
test Z*, based on the composite endpoint E*.  
As we have seen in the previous section, both tests under the null hypothesis are 
asymptotically N(0,1), and under a sequence of contiguous alternatives to the null hypothesis 
they are asymptotically normal with variance 1 and mean as per the conditions introduced in 













To turn this expression and the procedure behind into something useful for the design of 
clinical trials and interpretable for investigators, Gómez and Lagakos derived this expression to 
a much interpretable one based on some measurable parameters such as: 
• Frequencies P1 and P2 of observing endpoints E1 and E2 in treatment 0 (control); 
• The relative treatment effect on T1 and T2 given by HR1 and HR2 respectively; 
• The degree of dependence between T1 and T2 given by the Spearman’s rank 
correlation coefficient ρ. 
To come to that simplification the Weibull distribution has been chosen to represent the 
survival distributions, as it is widely used due to its flexibility, which allows hazard functions to 
increase, decrease, or remain constant, and mimic the behavior normal or exponential 
distributions. Taking into consideration assumptions described in section 3.1, the mentioned 


















































  (1) 
From expression (1) we note that, to calculate the ARE (Z*,Z), we need the following 
information: 
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• )()0(1 tf : the marginal density function for T1 in group 0; 


























= : the hazard ration of the composite endpoint 
But this expression does not seem yet as comprehensive as an investigator would expect, so it 
needs to be further developed and work out relations with parameters that could be obtained. 
As introduced in this section, the Weibull distribution has been chosen for the marginal laws of 





























 (k=1,2 depending if we refer to T1 or T2) 
where 
)( j
kb is the scale parameter and 
)( j
kβ  is the shape parameter. Again, as stated in 
assumption 3, we assume to have proportional hazards, meaning that both groups will have 




1 βββ == and 2)1(2)0(2 βββ == .  
Back to the information needed to compute the ARE, we are able now to say that both the 
density function and the survival function, )()( )0(1
)0(
1 uSuf ⇔ , can be described by the 
parameters ),( 1
)0(
1 βb .   
Regarding )()0(* tf , that describes the behavior of the composite endpoint in the T* in the 




* TTT = so that it requires information about 
)()0(1 tS and )(
)0(
2 tS . Similar to what we have done for )(
)0(
1 tS , we can say that )(
)0(
2 tS  can be 
expressed in terms of a Weibull function with parameters ),( )0(2
)0(
2 βb . 
With the information gathered so far we would be able to know the information for the first 
three bullet point we need  to calculate the ARE: )()0(1 tf , )(
)0(
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= ? This expression implies the knowledge of 
)()( )1(*
)1(
* tSt ⇔λ which involves ),()( 1)1(1)1(1 βbtS =  and ),()( 2)1(2)1(2 βbtS = . 
As it has been already said, and as per the proportional hazards assumption, we will fix 
1β and 2β , so the information we still need to get are the scale parameters: )0(1b , )0(2b , )1(1b and 
)1(




2b  are 
functions of (P1, 1β ) and (P2, 2β ) respectively, while the scale parameters )1(1b and )1(2b are 
functions of (
)0(
1b ,HR1) and (
)0(
2b ,HR2). Hence, the parameters needed to calculate the ARE can 
be summarised by: 
• 1β : shape of the marginal law of the relevant endpoint; 
• 2β : shape of the marginal law of the additional endpoint; 
• HR1 : hazard ratio of the relevant endpoint in the control group; 
• HR2 : hazard ratio of the additional endpoint in the control group; 
• P1: probability of observing the main endpoint in the control group; 
• P2: probability of observing the additional endpoint in the control group; 
• ρ: Spearman’s correlation between the relevant and the additional endpoint. 
We will evaluate the results of the ),( * ZZARE , and decide whether it is more beneficial to use 
overall survival or progression-free survival. 
• If ),( * ZZARE  > 1, the use of composite endpoints is recommended, meaning that the 
addition of progression (additional endpoint) to death provides an added value and 
increases the clinical trial efficiency. 
•  If 1),( * ≤ZZARE , then the relevant endpoint (death in our study) shall be considered as 
the primary endpoint alone. 
It must be said as well that in the boundaries of 1, the benefit of one endpoint over the over 
may be slight, so other factors rather than statistical shall be considered.  
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3.4. Statistical tools and programming  
 
All ARE calculations, charts and tables have been generated using R (version 2.11.1) 
programming. See code attached in 
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Appendix 4 – R Programming Code Used. Original ARE calculation programming was 
performed in MAPLE (v12) language and adapted to R by Moisés Gómez Mateu (Universitat 
Politècnica de Catalunya).  
Computations are based upon Gómez and Lagakos paper following the steps below: 
• A range of Spearman’s rank correlation values (ρ) are introduced and for each one the 
corresponding Frank’s copula association parameter (θ) is calculated. 
• Sets of values for (β1, β2, P1, P2, HR1, HR2) are provided. For each possible combination 
the ARE is computed following the method described in section 3.3.  
• The resulting values of the ARE for each combination of the above mentioned parameters 
are written in a database and used for the analysis of the convenience of choosing the 
composite endpoint versus the primary endpoint. 
• As mentioned in the previous section, the Weibull distribution has been chosen as it is 
widely used in survival analysis due to its flexibility. It allows for decreasing, constant and 
increasing hazard rates and mimics the behavior of other, e.g., normal and exponential, 
statistical distributions. Weibull distributions are define with two parameters: 
o the scale parameter: b(j) 
o the shape parameter: β(j) 
All parameters are combined with each other in order to set up all kind of scenarios. For each 
scenario the ARE value is calculated, and output saved in a separate database.  
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4. Bibliographic research 
 
4.1. Search algorithm 
 
As already mentioned, to be able to compile enough data to perform our study, a bibliographic 
research has been performed in some of most popular medical journals, with higher impact 
factor: 
Journal Impact Factor in 2010 
New England Journal of Medicine (NEJM) 53,480 
Journal of Clinical Oncology (JCO) 18,970 
British Medical Journal (BMJ) 13,471 
Annals of oncology (AoO) 6,452 
 
The first search algorithm was to look in each of these journals the key words breast and 
cancer and randomized in title or in abstract; and within a limited time period: from January 
2009 through December 2010; limited to papers publication date between 2009 and 2010, and 
only original papers, no reviews nor discussions. 
The first results obtained were summarized in the following table: 
  AoO BMJ JCO NEJM Total 
Number of randomized breast 
cancer clinical trials 
32 64 57 27 180 
 
Among the 180 articles, the following step was to check that the selected papers were clinical 
trials on breast cancer, either on early stages or advanced, and to discard meta-analysis and 
any review document selected by mistake. 
With this second filter, about half of the articles were discarded. The table below shows the 
remaining papers.  
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  AoO BMJ JCO NEJM Total 
Number of original articles 
16 2 47 27 92 
 
A second review was performed with the remaining papers to select only those ones which 
had survival endpoints under their objectives: time to progression (TTP), progression-free 
survival (PFS), disease-free survival (DFS) or Overall Survival (OS) as primary or secondary 
endpoint; and were phase II and III trials. Phase I trials were discarded since they are two small 
ones and whose objective is not survival. 
Thus, the pre-selected trials are the following ones.  
  AoO BMJ JCO NEJM Total 
Number of  phase II/III with 
survival endpoints 
14 0 26 8 48 
 
The final 48 selected were thoroughly reviewed to confirm they were eligible for this analysis. 
During this final one by one review, some papers were discarded because they did not met the 
criteria or did not contain enough information for our work. 
The main reasons for discarding are summarized in the following table:  
Reason to discard previous pre-screened papers:  
Not enough data 5 
Biomarkers trials 4 




After this final selection, the articles selection is from the following journals: 
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 AoO BMJ JCO NEJM TOTAL 
selected for data analysis 11 0 15 6 32 
 
With the 32 finally selected trials, a table was created to summarize and capture the following 
information: 
• Primary endpoint considered, and therefore which endpoint the trial is empowered to 
detect differences. 
• Secondary endpoint(s) 
• Trial Phase:  II / III 
• Disease stage: Early / Advanced breast cancer 
• Probability of the event in patients in the treatment and control arms 
• Hazard ratio obtained for each of the endpoints 
• P-value of each of the tests. 
• Test used for the analysis 
Appendix 1 shows the bibliographic details of the selected papers and Appendix 2 summarizes 
the data collected from each trial: 
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4.2. Brief articles’ outline 
 
Once compiled all the data from the selected papers, and before any analysis was performed, 
some considerations were taken: 
1. Since Disease-free Survival and Progression-free Survival are equivalent endpoints, i.e. 
the only difference is the disease phase and this has been categorized as well, both will 
be considered as the same composite endpoint. 
2. ORR information is not relevant for our objective, because it is not a time-to-event 
endpoint. Four trials (4, 6, 27 and 44) have ORR as its primary endpoint, so only 
information on primary analysis p-values has been recorded in our table, to distinguish 
those cases where this data was statistically significant or not.  
3. Three papers (5, 4 and 32) showed TTF as the primary endpoint. The FDA guideline on 
Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics state that TTF is 
not an appropriate efficacy endpoint because includes discontinuation from trial for 
any reason: disease progression, death or toxicity. Thus, no survival information from 
TTF will be used, other than the p-values, as they are set as the primary endpoint in 
their corresponding papers, similarly to what is being done for ORR. 
4. Per definition, Time to Progression is the time from randomization until objective 
disease progression, and death is censored (non-informative). 
5. All trials selected assessed differences between the treatment arms’ survival curves by 
means of the logrank. 
Having taken these considerations, the initial observations on the data selected were the 
following ones: 
1. In terms of primary endpoints used in the selected clinical trials, half of the trials had a 
composite endpoint – either PFS or DFS - as primary endpoint, while only 3 out of the 32 
(9.4%) uses OS as primary endpoint.  It is worthwhile to recall that the FDA 
recommended endpoint is the OS.  
Endpoint # % 
Overall Survival 3 9.4% 
Progression 6 18.8% 
Composite Endpoint 16 50.0% 
ORR / TTF 7 21.9% 
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Table 2 - Primary endpoints used on the selected clinical trials 
2. Regarding the secondary endpoints, 26 / 32 (81.25%) trials selected have OS as a 
secondary endpoint on their clinical protocols, while 9 / 32 (28.12%) have a composite 
endpoint.  
Endpoint # % 
Overall Survival 26 81.25% 
Progression 5 15.63% 
Composite Endpoint 9 28.16% 
ORR / TTF 1 3.13% 
Table 3 - Secondary endpoints used on the selected clinical trials 
From these initial observations we can observe that in breast cancer clinical trials there’s a 
tendency to use composite endpoints as a primary endpoint, and to add overall survival as 
secondary. Likewise, we can see that the majority of the trials use either composite endpoints 
or overall survival as endpoint – 29 / 32 (90.63%) OS and 25 / 32 (78.13%) CE – either as 
primary or secondary. 
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4.3. Setting of statistical parameters 
 
As mentioned in section 3 and in Gomez and Lagakos’ paper, to obtain the Asymptotic Relative 
Efficiency score, that will allow us to decide if we will have statistical benefit in our trial with 
the inclusion of the additional endpoint (progression) to the main endpoint (death) we need to 
set certain parameters in advance. These parameters are: 
• P1 : probability in the control group to find the main endpoint,  
• HR1: ratio of the hazard functions of the two treatment groups for the main endpoint,  
• P2: probability in the control group to find the additional endpoint, 
• HR2: ratio of the hazard functions of the two treatment groups for the additional 
endpoint 
• ρ: Spearmen’s correlation index between both endpoints 
• β: shape parameter of the Weibull function.  
In the reality, each of the above parameters may adopt different values in each situation, i.e.: 
we may expect that in our target population only 20% of patients developing disease relapse in 
the control group, and overall we are optimistic and expect to have only 2% of deaths (by any 
cause). We may have the same situation with the hazard ratio values. Depending on what we 
expect to gain with the experimental treatment against the control group, we will adopt 
different values of the Hazard ratio for our estimations. 
It is important to remark at this point, and due to the fact that all clinical trials are designed to 
show either superiority or non-inferiority of the treatment group against the control, that 
although in our literature research we found that some HR values >1 (meaning that the control 
group had better survival or less progression than the experimental group), we set the limit of 
these hazard ratios to 0.99, meaning that the although minimal, a benefit over the control 
group is always expected when an investigator set up a clinical trial. The reason for that is that 
we assumed no investigator will design a clinical trial to show that the control group is better 
than the experimental one, and even though it can be designed to show non-inferiority, we set 
as an upper limit (HR≤0.99). 
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With regards to the Spearmen’s correlation index (ρ), we have defined three levels of 
correlation between endpoints: 
• weak correlation: 0.15 
• mild correlation: 0.45 
• high correlation: 0.75 
Although the correlation parameter may adopt values from -1 to 1, we used three positive 
values only. By this we assume that the relation between death and progression is positive, i.e. 
when progression increases, we foresee an increase on the number of deaths. Likewise, since 
we will try to focus the results from an investigator perspective, we categorized the correlation 
in only three levels, which we would expect that at this extent an investigator would be able to 
provide information on the expectations about the correlation between the endpoints. 
Finally with regards to the Weibull shape parameter, β may take values <1, 1 and >1, 
depending if we consider that the hazard ratio is decreasing with time, constant and increasing 
respectively. Since the data considered here is from breast cancer data, it is easy to assume 
that the risks over that time remains constant or even increase once the cancer is detected. 
But there is literature supporting the curability of the disease after certain time28-30, so we 
have included in our assessment a decreasing risks model for patients at early stages of the 
disease. It’s the work of the investigator to find out the more reliable anticipated values of 
these parameters before calculations sample size and design the trial. 
 
4.3.1. Potential Covariables 
 
As we have seen, it is of great importance the values of the Probabilities and the Hazard Ratios 
obtained from the literature. These variables aim to represent the real values an investigator 
would have or estimate during the design phase of a clinical trial. These estimations condition 
the number of events needed to see statistically significant efficacy differences, and thus the 
size of the trial sample needed. 
Therefore, and with the objective to estimate as accurate as possible the ranges in which 
probabilities and hazard ratios may be found, the first step in our exploratory analysis was to 
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determine if there was any other variable from those recorded that we should take into 
consideration in our analysis. 
Figure 4 – P and HR differences per disease stage and trial phase with pooled data shows P and HR 
distributions taking into consideration the Disease Stage and the Clinical Trial Phase. It clearly 
showed that depending on the disease stage of the trial, i.e.: Advanced breast cancer or Early 
breast cancer, the Probabilities for death and/or progression are different, so it was taken the 
decision to consider separately, and therefore generate two study lines, for Early and 
Advanced stages of the disease.  
With regards to the Trial Phase, no such big differences were detected neither for Probabilities 
nor Hazard Ratios, but further plots were performed to explore if differences from a trial phase 
perspective should be taken into consideration. 
It is important to highlight that the P and HR values on Figure 4 does not distinguish on death, 
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Figure 4 – P and HR differences per disease stage and trial phase with pooled data 
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To confirm these observations, it was repeated the exploration of Probabilities and Hazard 
ratios splitting them for all different type of endpoints: death (P1 and HR1), progression (P2 
and HR2), and composite endpoints (P3 and HR3). 
The result of this analysis is shown in figures Figure 5 - Probability differences per disease 
stage with pooled data, Figure 6, Figure 7 and Figure 8, which confirms that: 
• The probability of all of the considered survival endpoints is higher in those trials with 
Advanced Cancer Patients than in those with Early Breast Cancer. This conclusion does 
make sense, as the probability of worsening/progression and death is higher with 
patients in an advanced stage of the disease.  
• Perhaps due to that the amount of phase II clinical trials data was less than what was 
obtained from phase III trials, we could not conclude that the probabilities of each 
endpoint are different depending on the trial phase. However, we should not be able 
to detect any difference in this regard, and most of the phase II trial that is positive 
continues with similar phase III. As previously introduced here, phase II trials are in 
general “pilot” trials to confirm safety of the treatment being tested. If the safety 
profile of the experimental treatment is acceptable, then phase III trials are set up 
with patients of similar characteristics. 
• As foreseen in figure 4, no difference is observed in terms of hazard ratios for early or 
advanced clinical trials. 
• Again perhaps due to the reduced number of phase II trials we are not able to observe 
differences on the hazard ratios between trial phases. 
According to this exploratory analysis results, we will consider the disease stage as a 
covariable in our study, due to the differences observed in the death and progression 
probabilities, but discard the trial phase, as it would not make sense neither from a clinical 
perspective. 
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Composite Endpoint as primary endpoint
 
Figure 5 - Probability differences per disease stage with pooled data 
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Composite Endpoint as primary endpoint
 
Figure 6 - Probability differences per trial phase with pooled data 
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Progression as primary endpoint




































Composite Endpoint as primary endpoint
 
Figure 7 - HR differences per disease stage with pooled data 
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Composite Endpoint as primary endpoint
 
Figure 8 - - HR differences per trial phase with pooled data 
Master’s Degree Thesis      MSc in Statistics and Operations Research 
 55 
4.3.2. Correlation between T1 and T2 
 
Reporting differences on survival events considering different the disease stage has been 
widely reported in the last decades
28
. As described, our methodology based on Gómez and 
Lagakos paper defines the correlation between the two events of interest. In our study death 
is the event of interest and progression the additional that combined conform the composite 
endpoints.  
By accepting that patients detected at an early stage of the disease have better prognosis and 
survival than those patients in advanced breast cancer, either because the type of the disease 
is more aggressive, or because the disease is consequence of a previous cancer, we accept that 
progression in the early stage is less likely to happen than in advanced breast cancer. Thus we 
can assume that progression and death are less correlated in early breast cancer stages than in 
advanced. Hence, when we established the correlation (Spearman’s correlation: ρ) between 
progression and death, we set it differently for each disease stage: 
• For Early Breast Cancer patients we tested weak (0.15) and mild (0.45) correlation,  
• For Advanced Breast Cancer patients we tested medium (0.45) and strong correlation 
(0.75). 
 
4.3.3. β Values for marginal Weibull laws 
 
For the same reason, and we have already explained, a patient who is diagnosed of breast 
cancer at an early stage may be considered as cured by some authors, although this is actually 
under discussion. We assumed in this study different hazard function shape parameters for 
each disease: 
• For Early Breast Cancer patients we tested decreasing (0.5), constant (1) and increasing 
(2) hazard functions, 
• For Advanced Breast Cancer patients we tested constant (1) and increasing (2) hazard 
functions. 
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4.3.4. Clustering of Probabilities and Hazard Ratios 
 
Apart from deciding the use of Disease Stage as a covariable and analyze our data in two 
different scenarios: (0) Early breast cancer and (1) Advanced breast cancer, we intended to 
look for any pattern of association between probabilities and Hazard Ratios in our data, which 
would allow clustering our data. 
As mentioned before, since an investigator willing to test a new treatment against the 
available one would never consider that the new treatment may be worse than the control, we 
capped all HR values to 0.99. Namely, even minimal, the investigator will always assume that 
his treatment is better than the one being tested.  
To perform this, we plotted P1 against HR1 and P2 against HR2, the values we will need to 
calculate the ARE, distinguishing per each disease stage 0 and 1. 
Note that the y axis reads P01 and P02. The 0 right after the P refers to the control arm. 
Remind that only probabilities and hazard ratios from the control group are considered to 
calculate the Asymptotic Relative Efficiency.  
As seen in Figure 9 - Data plot for cluster identification, the only pair of data that allows 
the identification of clusters is P1 and HR1 at stage 0 (early Breast Cancer). For the rest of 
scenarios there was not enough data to identify any potential cluster.  
The cluster identification was performed following the K-means clustering method in R, as 
described by Everitt & Hothorn
31
, which calculates distances from each point to a centroid 
point and defines the clusters. Seen the reduced amount of data available, it was decided that 
the optimal amount of clusters would never be higher than 3, so it was compared the results 
for a 2 clusters design against a 3 clusters. 
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P02 and HR2 distr - Disease Stage 1
 
Figure 9 - Data plot for cluster identification 
The results can be seen in Figure 10 - Stage 0 P1 and HR1 plot of the 2 clusters design and Figure 11 
- Stage 0 P1 and HR1 plot of the 3 clusters design. These two plots identify, in function of main 
components, which are the most appropriate clusters. As showed as well in the picture, the 2 
clusters model explains more variability, 96.26% from our data, against the 94.38% of the 3 
cluster model. However, and given the objective of our study, it was decided to consider the 3 
clusters design, as the 2 clusters model embraced a wide number of observations, that could 
make our post-analysis interpretations too general. The values of these cluster components 
are, thus:  
Cluster P1 HR1 
1 0.070 0.976 
2 0.330 0.803 
3 0.133 0.730 
Table 4- Cluster values for P1 and HR1 in disease stage 0 
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Figure 10 - Stage 0 P1 and HR1 plot of the 2 clusters design 
 
 













































Figure 11 - Stage 0 P1 and HR1 plot of the 3 clusters design 
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4.3.5. Summary of values taken for ARE computation 
 
Having considered the above points, and according to the values obtained from the literature 
for P1, P2, HR1 and HR2 at each disease stage, these are the values that will be used for the 
ARE calculation of this study. 
• Disease Stage 0 (Early Breast Cancer) 
(P1,HR1) P2 HR2 beta 1 beta 2 rho 
(0.070 , 0.976) 0.067 0.650 0.5 0.5 0.15 
(0.330 , 0.803) 0.163 0.840 1.0 1.0 0.45 
(0.133 , 0.730) 0.222 0.990 2.0 2.0  
Table 5- Values for ARE computation for Early Breast Cancer data 
Identified in green is the cluster described in section  4.3.4 
• Disease stage 1 (Advanced breast cancer) 
P1 P2 HR1 HR2 beta 1 beta 2 rho 
0.480 0.560 0.663 0.704 1.0 1.0 0.45 
0.615 0.763 0.840 0.800 2.0 2.0 0.75 
0.746 0.811 0.966 0.900       
      0.990       
Table 6- Values for ARE computation for Advanced Breast Cancer data 
 




5.1. ARE calculations 
 
The objective of this Master Thesis is to study the behavior of the Asymptotic Relative 
Efficiency (ARE) under different scenarios by means of the methodology described in Gomez 
and Lagakos’ paper, applied to breast cancer data. Briefly, the ARE value compares the 
efficiency of two clinical trial endpoints: a single one (death) and a composite one (death plus 
progression) and is able to provide us guidance on which is the best endpoint to be used in a 
potential clinical trial we may consider to set up. We applied this methodology to breast 
cancer data obtained from randomized clinical trials published during 2009 and 2010, with the 
intention to define realistic data ranges an investigator might find on their day to day patients. 
This led to realistic and interpretable results, what we are describing in this section. 
We focused on the two main events considered in survival analysis in cancer: death and 
progression. Overall Survival (time from treatment allocation until death for any reason) is the 
most recommended endpoint by the regulatory agencies, but quite often, as we have 
observed in section  4.2, disease progression is added to death (if the investigator or sponsor 
may foresee long follow-up, for example), and derive to what is known as Progression-free 
survival: time from randomization until progression or death, whichever comes first. 
Based in real data obtained from the articles, and with the perspective and information an 
investigator would have during the early stages of a protocol design, we describe here the 
results of all the scenarios created with the data available in section  4.3.5. 
As a reminder, the five parameters we need to calculate the ARE are the following ones: 
• P1 and P2: the probabilities of death (main endpoint and defined as “1” in our case), 
and progression (additional endpoint and defined as “2”) on the control group. 
• HR1 and HR2:  hazard ratio of our endpoints of interest. 
• β1 and β2: shape of the marginal Weibull laws governing time to death and time to 
progression, respectively.  
• ρ: Spearman’s correlation between the main event and the additional endpoint. 
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In section  4.3.1 we took the decision, based on the results of the exploratory analysis, that we 
would perform the analysis separately for Early Breast Cancer (stage 0) and Advanced Breast 
Cancer (stage 1) data. Thus, the number of scenarios, combination of the parameters 
introduced in section 5.3.5 is: 
• Stage 0: 486 different scenarios 
• Stage 1: 864 different scenarios 
Once calculated the Asymptotic Relative Efficiency score, the output was coded to 0 when the 
ARE ≤ 1, so that the recommendation would be NOT adding progression to death, meaning to 
keep Overall Survival as primary endpoint in our trial; or coded to 1 if ARE > 1, where we would 
recommend the addition of progression to death, and therefore the use of the composite 
endpoint Progression-free Survival. 
As we said we intend to interpret the results from an investigators perspective, bearing in 
mind the information an investigator may be able to provide during the set up phase of a 
clinical trial. Most probably, an investigator thinks only in how much benefit from the 
experimental treatment he/she expects to find:, i.e. reduction on the number of deaths or 
patients that expects to progress (hazard ratios) and he/she might be able to know or expect 
the probability of death (P1) and progression (P2) on the control arm. 
We are aware that correlation between endpoints is not a concept that an investigator is used 
to think on, as they might do with hazard ratios and probabilities, so to ease their job and 
make it as simple as possible we have considered only three levels: weak, moderate and strong 
correlation, measured here by the Spearman’s Correlation index. We assume an investigator 
may understand the principles of correlation, i.e. understand what the correlation is, and 
might be able to suggest its level between death and progression. 
Results are presented in this perspective, showed in tables with the percentage of cases where 
the use of the progression-free survival is recommended rather than overall survival. 
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5.2. Early Breast Cancer Results (Stage 0) 
 
5.2.1. Comparing main endpoint and additional endpoint through their Hazard 
Ratios 
 
We will discuss in this section the situation where the investigator is able to give us 
information about the hazard ratio expected to be observed in terms of the main endpoint 
(death), and could also be able to give us information about the hazard ratio that might be 
observed if we would focus on disease progression. 
 Tables 7 and 8 show the percentage of scenarios, given HR1 (hazard ratio of death), and HR2 
(hazard ratio of progression), with rho values 0.15 (weak correlation between them) and 0.45 
(moderate correlation). 
The first thing we can see when we look at the results of the ARE calculation for those 
scenarios considering weak correlation, is that there are two different but very clear situations: 
scenarios where the use of composite endpoint is recommended in 100% of the cases, and 
those where its use is not recommended at all. For instance, at both correlation levels 
considered in disease stage 0, when the HR2 is lower (less number of progressions expected, 
so more beneficial for patients) than the expected HR1, in all cases (100%) the ARE score 
recommends the use of the composite endpoint. Meaning that in cases where we expect to 
see a low HR2 value and this value is even lower than HR1, the use of composite endpoint will 
be in all circumstances recommended. 
On the other hand, scenarios where HR2 is not expected to show much benefit (HR2=0.99), 
and the HR1 values are ≤0.803, the use of composite endpoints is contraindicated, and is death 
the only endpoint that shall be used, thus Overall Survival.  
It must be highlighted though, that in these scenarios where an investigator may expect very 
mild benefit on the additional endpoint, where in most cases the investigator would not 
include the endpoint, we observe that if we expect an HR1 value of 0.976, in 55.6% of the 
cases the inclusion of progression would be advisable, and the composite endpoint might be 
the recommended endpoint. In other words, if we would not expect a big effect in terms of 
death differences between the treatment groups, we would consider the addition of 
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progression in roughly half of the situations even if we didn’t expect either big difference 
between groups.  
If we focus on HR1 values now, we have already seen that if HR2 is lower that that, the use of 
the composite endpoint is recommended. But for values of HR1 = 0.73 (the most positive of 
the values we have used in our calculations, meaning that we expect a high reduction on the 
number of deaths on our experimental group), we see how for values of HR2 of 0.84, the use 
of composite endpoint is still recommended in 77.8% of the cases, and drops to 0% when the 
HR2 value is 0.99. As the HR1 value increase (less effect over the control group), we see how 
for values of HR2=0.84 the percentage of scenarios where we would recommend the use of 
the composite endpoint would increase to 100%. 
Likewise, if instead of weak correlation between death and progression we consider that 
there’s a moderate correlation situation (ρ = 0.45), we observe that the pattern is similar to 
what we have seen with ρ =0.15. For positive values of HR2 (0.65), it is always recommended 
to use the composite endpoint independent of the HR1 value (at the selected values). 
It is worthwhile to highlight how the increase of the dependence between both endpoints 
affects the ARE score. We can see in (HR1,HR2) = (0.803,0.84), how when death and 
progression are almost independent, the percentage of cases where the composite endpoint is 
recommended is 100%, while when  we increase the correlation between them, this 
percentage drops until 11%; and when (HR1,HR2) = (0.73,0.84), when ρ = 0.15, the percentage 
of scenarios where composite endpoints is recommended is 77.8%, while when ρ = 0.45, this 
value turns to 3.7%.  In line with this observation, it’s important to highlight how in scenarios 
where we combine high HR1 values (0.976) with HR2=0.99, the addition of progression is not 
recommended at all (0% of the cases), while with low correlation we observed that in 55.6% of 
the cases it was recommended. Looking at scenarios where we to have HR2 values around 
0.84, the use of composite endpoint is recommended only when the HR1=0.976. 
It is important then to highlight how the effect of the increase of the correlation between both 
endpoints results in a reduction of the ARE score, and therefore in a reduction on the cases 
where the composite endpoint is recommended. 
HR1 | HR2 0.65 0.84 0.99 
0.73 100.0% 77.8% 0.0% 
0.803 100.0% 100.0% 0.0% 
0.976 100.0% 100.0% 55.6% 
Table 7- stage 0 HR1/HR2: % of scenarios where CE is recommended with ρ=0.15 
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HR1 | HR2 0.65 0.84 0.99 
0.73 100.0% 3.7% 0.0% 
0.803 100.0% 11.1% 0.0% 
0.976 100.0% 100.0% 0.0% 
Table 8 - stage 0 HR1/HR2: % of scenarios where CE is recommended with ρ=0.45 
 
5.2.2. Comparing main endpoint and additional endpoint Probabilities 
 
We may find the situation where our investigators’ team would have an idea on the probability 
of the death in our control group, and is able to come up with an expected probability to find 
progression in the same group. We compared those situations where we would need to decide 
whether we should use the main endpoint only or adding progression based only in the 
probability of these events. The results are summarized in tables 9 and 10, again taking into 
account the correlation between progression and death. We see in this case a pattern not as 
conclusive as we had seen with the hazard ratios. 
In all cases, at given P1 (probability of death in the control group), the percentage of scenarios 
where the additional endpoint is recommended to be used increases with P2 (probability of 
progression in the control group), either when there is a weak correlation or when there’s a 
moderate one between endpoints. We can see how for P1=0.07 (lowest level of probability 
considered), even for P2=0.07 values, the addition of progression is recommended in 66.7% of 
the cases, and how this increase until 100% of the cases when P2=0.22. 
Likewise, we see how for high P1 values (P1=0.33), for P2=0.01 the composite endpoint is 
recommended in 33% of the cases, and 66.7% when P2=0.22 (the highest level considered). 
Having said that, we observed as mentioned on section  5.2.1 that any increase of the 
correlation between endpoints causes a reduction of the ARE results, which derives to a lower 
percentage where the composite endpoint is recommended. As an example, for a P1=0.07 and 
P2=0.16, we have that for a low correlation (ρ=0.15) the percentage of recommendation to use 
a composite endpoints is 88%, while if we increase the expected correlation to 0.45, the 
percentage of cases where the use of composite endpoint is recommended is 66.7%.  
 
P1 | P2 0.07 0.16 0.22 
0.07 66.7% 88.9% 100.0% 
0.133 33.3% 66.7% 66.7% 
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0.33 33.3% 66.7% 66.7% 
Table 9 - stage 0 P1/P2: % of scenarios where CE is recommended with ρ=0.15 
 
P1 | P2 0.07 0.16 0.22 
0.07 66.7% 66.7% 66.7% 
0.133 33.3% 33.3% 37.0% 
0.33 33.3% 33.3% 44.4% 
Table 10 - stage 0 P1/P2: % of scenarios where CE is recommended with ρ=0.45 
 
At this point we have checked death and progression as endpoints in terms of hazard ratios 
and probabilities. If we would be asked now based in which parameters we could easily take a 
decision, it is clear that the analysis of the hazard ratios provided recommendations of either 
100% or 0% of cases in 6 or 7 out of the 9 scenarios, while if we check the probabilities, only in 
1 case scenario 100% of the cases recommended the addition of progression to death. 
 
5.2.3. Checking (P1, HR1) against P2 
 
To reduce the number of scenarios, and since the data available allowed us building clusters 
for P1 and HR1, we analyze in the following two sections how these chosen clusters combine 
with P2: the expected probability of progression in the control arm; and HR2: the expected 
hazard ratio for progression. 
As described in section  4.3.4, we clustered the data in three groups. We distinguish one where 
death has a low probability (P1=0.07) of being observed in the control group, and where we do 
not expect either to detect a big benefit in terms of the hazard ratio (HR1=0.976). In these 
situations, the addition of progression, even if the probability of detecting progression is low 
(P2=0.07), the percentage of scenarios where the composite endpoint is recommended in 
66.7%, and increases when P2=0.16 to 88.9% of the cases, and it is recommended in all cases 
when P2=0.22. It is worthwhile to highlight that in the first case where P2=0.07, investigators 
might have declined the suggestion of adding progression due to the low probability of 
observing that, but the ARE results show how in almost 67% of the cases its addition is 
supported. 
With regards to the other two clusters, we see how for cluster (P1, HR1) = (0.330,0.803), the 
percentage of cases where the composite endpoint is recommended is 66.7% for all values of 
P2 considered. And we observe something similar with the third cluster (0.133,0.730): if the 
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investigator would expect a probability to identify progression of 0.07, its addition would be 
recommended in 44.4% of the cases, increasing to 66.7% for P2 values of 0.16 and 0.22.  
Similar to what has been observed in sections  5.2.1 and  5.2.2, we observe how these results 
are affected with the increase in the expected correlation between endpoints (from ρ=0.15 to 
ρ=0.45). And as happened in scenarios with expected Spearman’s correlation index ρ=0.15 we 
observe that for each cluster, the percentage of scenarios where the composite endpoint is 
recommended remains barely constant for each of the P2 values.  Namely, we observe again 
how for cluster: (0.07,0.976)  it is recommended the addition of progression in 66.7% of the 
cases for P2 values of: 0.07, 0.16 and 0.22; and between 33% and 44% for clusters 
(0.330,0.803) and (0.133,0.730). 
We defined all parameters’ ranges based on real data from the literature, but seen the results 
obtained here, it would have been interesting to observe the behavior of the ARE beyond the 
upper and lower limits to confirm if it does remain constant and if not, we could have 
estimated from which values it increases or decreases. 
 
(P1,HR1) | P2 0,07 0,16 0,22 
(0.07,0.976) 66.7% 88.9% 100.0% 
(0.330,0.803) 66.7% 66.7% 66.7% 
(0.133,0.730) 44.4% 66.7% 66.7% 
Table 11 - stage 0 (P1,HR1) /P2: % of scenarios where CE is recommended with ρ=0.15 
 
(P1,HR1) | P2 0,07 0,16 0,22 
(0.07,0.976) 66.7% 66.7% 66.7% 
(0.330,0.803) 33.3% 33.3% 44.4% 
(0.133,0.730) 33.3% 33.3% 37.0% 
Table 12 - stage 0 (P1,HR1)/P2: % of scenarios where CE is recommended with ρ=0.45 
 
5.2.4. Checking the (P1, HR1) cluster against HR2 
 
In line with what has been done for section  5.2.3, we compared the clustered data of (P1, 
HR1), with the chosen ranges for HR2, the effect on progression that we would expect in our 
trial. Table 13 - stage 0 (P1,HR1)/HR2: % of scenarios where CE is recommended with ρ=0.15 and 
Table 14 - stage 0 (P1,HR1)/HR2: % of scenarios where CE is recommended with ρ=0.45 summarize 
the results. 
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We observe, similar to what we did before, how for HR2 values of 0.65, the addition of 
progression is recommended in 100% of the cases for ρ=0.15 and ρ=0.45. On the other hand, 
and as we could foresee, in most of the cases when HR2=0.99 (very mild effect over 
progression expected), the addition is not recommended.  Again, it is worthwhile to highlight 
that for scenarios where a weak correlation is expected (ρ=0.15), in trials belonging to the 
(0.07,0.976) cluster and HR2 expected of 0.99, the addition of progression is recommended in 
55.6% of the cases, which would be interesting for investigators. 
It is interesting the behavior of the ARE score for HR values of 0.84. We can see how for trials 
adhered to the first cluster (0.07,0.976), both with weak or medium correlation, the addition 
of progression is always recommended, while for those in  (0.133,0.730) cluster, we see how 
the ARE results do not recommend its addition, or in very few cases. Finally, we can see the 
relevant effect of the correlation in trials included in cluster (0.330,0.803), for which at soft 
correlation scenarios would recommend the use of composite endpoint in 100% of the cases, 
while if it does increase (ρ=0.45), the percentage of cases falls until 11.1%. 
 
(P1,HR1) | HR2 0,65 0,84 0,99 
(0.07,0.976) 100.0% 100.0% 55.6% 
(0.330,0.803) 100.0% 100.0% 0.0% 
(0.133,0.730) 100.0% 77.8%* 0.0% 
Table 13 - stage 0 (P1,HR1)/HR2: % of scenarios where CE is recommended with ρ=0.15 
*33% of the total number of scenarios had an ARE <1.1 
 
(P1,HR1) | HR2 0,65 0,84 0,99 
(0.07,0.976) 100.0% 100.0% 0.0% 
(0.330,0.803) 100.0% 11.1% 0.0% 
(0.133,0.730) 100.0% 3.7% 0.0% 
Table 14 - stage 0 (P1,HR1)/HR2: % of scenarios where CE is recommended with ρ=0.45 
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5.3. Advanced Breast Cancer Results (Stage 1) 
 
Following the same procedure as what has been done for Early Breast Cancer data, we looked 
at Advanced Breast Cancer ARE scores and determined its results in function of the parameters 
investigators may use during the set up phase of a clinical trial (probabilities and hazard ratios). 
The main difference between stage 0 and stage 1 data can be found in the probabilities of 
observing the events. For stage 0 we found probabilities: 
• P1:  0.07, 0.133 and 0.330;  
• P2: 0,07, 0,16 and 0,22 
while for stage 1 we have:  
• P1: 0.48, 0.615 ad 0.746 
• P2: 0.56, 0.763 and 0.811 
We shall bear in mind that a patient detected of breast cancer at an early stage of the disease, 
during a routine check, has a wide range of treatment possibilities: chemotherapy, radiology, 
surgery, which provides the patient the possibility to be considered “clean” at the end of the 
treatment period, and thus very low probability of observing death or progression. On the 
contrary, patients with an advanced breast cancer are usually patients with metastatic 
diseases (cancer is widespread in other body locations), and some of them may have 
undergone already surgery and chemotherapy treatment. In these patients we observed an 
increased probability of observing death and progression. 
As already highlighted, the correlation between the main endpoint (death) and progression) is 
also different to what we have used for early breast cancer data. Seen this increase on the 
probabilities, and the status of the patients, we have considered all scenarios with moderate 
(ρ=0.45) and strong correlation (ρ=0.75). 
 
5.3.1. Comparing the main endpoint’s and additional endpoint’s Hazard Ratios 
 
The first conclusion that could be drawn from the data summarized in tables Table 15 and 
Table 16, is that almost in all scenarios where the expected HR2 value is better that HR1, the 
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ARE recommends the addition of progression and use the composite endpoint in the clinical 
trials. 
From the data analyzed, this conclusion has only two exceptions. At the highest correlation 
model considered, spearman’s correlation index of 0.75, when HR1=0.84 and HR2=0.80, 
although HR2 is slightly better than HR1, the ARE does not recommend in any case the 
inclusion of progression. 
The second exception observed may be due to the same effect as the observed in the early 
breast cancer data: an increase in the correlation between endpoints makes decrease the ARE 
results. We can see how in scenario with Spearman’s correlation index of 0.45 and HR1=0.84 
and HR2=0.80, the percentage of scenarios for which we would recommend the composite 
endpoint in 100%, while in the scenario with a ρ=0.75, this percentage falls to 0%. 
Finally, in scenarios with the lowest HR1 considered (0.663) and the lowest HR2 (0.704), i.e. we 
have the best case scenario where it is expected to observe an important improvement in 
terms of death and progression, we see how, for both moderate and high correlation 
scenarios, the ARE recommends the use of composite endpoint in 66.7% and 58.3% of the 
cases respectively. 
 
HR1 | HR2 0.704 0.80 0.90 0.99 
0.663 66.7% 0.0% 0.0% 0.0% 
0.84 100.0% 100.0% 0.0% 0.0% 
0.966 100.0% 100.0% 100.0% 0.0% 
Table 15- stage 1 HR1/HR2: % of scenarios where CE is recommended with ρ=0.45 
 
HR1 | HR2 0.704 0.80 0.90 0.99 
0.663 58.3% 0.0% 0.0% 0.0% 
0.84 100.0% 0.0% 0.0% 0.0% 
0.966 100.0% 100.0% 100.0% 0.0% 
Table 16 - stage 1 HR1/HR2: % of scenarios where CE is recommended with ρ=0.75 
 
5.3.2. Comparing the main endpoint’s and additional endpoint’s Probabilities 
 
As we can observe in tables Table 17 and Table 18, for any P1 and P2 combinations, the use of 
composite endpoint is recommended in roughly the 50% of the cases, which we may interpret 
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as if the frequencies of observing either endpoint are not conclusive and may not be used to 
determine whether or not we should use the composite endpoint. 
Likewise, we can see how the effect of the correlation that we have seen in the sections 
before, is diluted when comparing P1 and P2. We can see how both tables may be summarized 
in a singe one. 
As a conclusion of the results below, we could say that the comparison between P1 and P2 
values in the ranges taken from clinical trials with advanced patients does not really give a 
clear clue on the strategy to follow, and would not be a case to consider in a potential real 
case. 
 
P1 | P2 0.56 0.763 0.811 
0.48 50.0% 50.0% 50.0% 
0.615 47.9% 50.0% 50.0% 
0.746 43.8% 41.7% 41.7% 
Table 17 - stage 1 P1/P2: % of scenarios where CE is recommended with ρ=0.45 
 
P1 | P2 0.56 0.763 0.811 
0.48 47.9% 50.0% 50.0% 
0.615 43.8% 50.0% 50.0% 
0.746 43.8% 41.7% 41.7% 
Table 18 - stage 1 P1/P2: % of scenarios where CE is recommended with ρ=0.75 
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6. Discussion and Recommendations 
 
In general, we have seen that in those scenarios where the investigator expects (1) low hazard 
ratio values, what means a reduction on the number of deaths in the experimental group with 
respect to the control one, or (2) high probability of observing death in our control arm (high 
P1) the addition of the secondary endpoint is only recommended in those cases where HR2 
and P2 values are similar to HR1 and P1, or HR2 values are lower than HR1 and P2 higher than 
P1. In other words, if an investigator expects a high reduction on the number of deaths in the 
experimental arm (HR1∼0.7), or the probability of death is high (P1=0.3 in early breast cancer 
and P1=0.74 in advanced breast cancer), the most efficient endpoint will be Overall Survival, 
unless HR2 is lower and P2 higher than HR1 and P1 respectively. 
Likewise, if we would consider the addition of progression to our clinical trial endpoint, and we 
would be expecting low HR2 values – reduction on number of patients that progressed – of 0.7 
or lower, in most of the cases the use of the composite endpoint is recommended irrespective 
of the values of the rest of parameters. This means that if the difference between the 
observed number of deaths from both treatment arms is equal or higher than 30%, the 
addition of progression to the clinical trial endpoint will always increase the statistical 
efficiency.  
We have not seen, though, such a clear effect of P2 – probability of observing patients that 
progressed in the control arm – in terms of deciding whether or not the composite endpoint is 
recommended, although we identified a trend: high P2 values increase the number of 
scenarios where it is recommended the addition of progression. 
Furthermore, we observed that: 
• There is an inverse relation between HR1 or P1 and the percentage of scenarios where the 
use of composite endpoint is recommended. The lower HR1 is, or the higher the expected 
P1 value is, the lower is the ARE value obtained, and hence less cases where the use of 
composite endpoint is recommended. 
• This relation turns to directly proportional when we look at the additional endpoint 
information (HR2 or P2). In those scenarios where we have low HR2 (high benefit in terms 
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of progression) and high P2 values, the ARE value increases and thus the percentage of 
scenarios where the composite endpoint is recommended as well.  
Apart from this, we should take into consideration the correlation between endpoints, death 
and progression. We observed that the recommendations may vary depending on the breast 
cancer stage, as we have summarized in the following sections  6.1.1 and  6.1.2. In cancer, these 
correlation differences might be linked to the time between both endpoints. In early breast 
cancer, progression and death are less correlated and thus the time from progression until 
death - if this is ever observed - is longer than in advanced breast cancer, where progression 
and death are more correlated and closer in time. Hence, it makes more sense in early breast 
cancer scenarios to include progression as an endpoint. Taking care of the disease progression 
concerns patient’s quality of life so if we expect to reduce the number of disease progressions 
with our experimental treatment, we are improving patient’s quality of live even if not 
improving the overall survival and this would still be adding a clinical benefit on patient’s life. 
We should obviously take toxicological considerations to make such statements about quality 
of life, but we are assuming here that less rate of disease progression is translated in an 
increase of patients’ quality of life. 
However, in advanced breast cancer progression and death are more correlated and closer in 
time, so from a clinical perspective this could mean that a patient that progressed is more 
likely to die than another one that did not progressed. In this case, observing progression 
increase the probability of observing death, so in some cases detecting progression would not 
add any value neither from a statistical perspective nor clinical. 
Since the ranges of HR and P are different for both disease stages, we can not derive the 
reason of the effect of correlation over the scenarios, but only mention potential causes that 
should be analyzed in future works: 
• Stage 1 P ranges were higher than stage 0 ones, so it could be that the effect of the 
correlation’s dilution is due to these higher values. Meaning that the correlation effect is 
observed mainly for low probability values, while this effect is not observed as we increase 
them. 
• Likewise, we tested only low (ρ=0.15) and medium (ρ=0.45) correlation for early breast 
cancer data, and medium and high (ρ=0.75), so another reason might be that the effect of 
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the correlation is high when both endpoints are not correlated, while this correlation 
softens as we increase the correlation between these. 
Apart from identifying trends and see how the Asymptotic Relative Efficiency behaves wit the 
different parameters considered, we tried to identify rules and define guidelines for future 
investigators that might consider the use of this procedure to assess. 
As a result of our simulations, where we analyzed all possible scenarios with combinations of 
the parameters required to calculate the ARE: P1, P2, HR1, HR2, β1, β2 and ρ we are able to 
derive the following guidelines or recommendations:  
 
6.1.1. Early Breast Cancer data interpretation 
 
1. If the expected HR2 value is low - ≤0.65 in our study -, the added value of the additional 
endpoint is enough to recommend the inclusion of progression in all cases. Therefore the 
use of composite endpoint is always recommended indistinctly of the rest of the 
parameters.  
A significant benefit over the disease progression may be translated into an increase on 
the quality of patient’s life, which is turning to be an actual objective of oncologists in 
general. As discussed in the introduction, increasing patients’ life should not be the only 
objective of our investigators. The quality of life an investigator may be able provide to 
these patients sometimes is as important as the time they live. We should definitely 
include progression, because by reducing the rate of patients that progress, we increase in 
most of the cases the quality of our patients’ life. 
2. In early breast cancer we considered low (ρ=0.15) and medium (ρ=0.45) correlation 
between death and progression. We observed how whenever the correlation between T1 
and T2 increases, the ARE value decreases under equal conditions of HR1, HR2, P1 or P2. 
This means that the increase of the level of correlation is more conservative and restrictive 
with regards to the addition of progression and to recommend its inclusion as part of a 
composite endpoint. In other words, as the correlation increases, the effect of addition of 
progression to our endpoint provides less information. It is important to highlight that the 
investigator can not control the level of correlation between death and progression. As it 
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has already been explained in this study, the investigator is asked during the set up phase 
of the clinical trial the expected grade of correlation between progression and death, to be 
able to predict as accurate as possible the efficiency of single endpoint and the composite 
one.  
3. When the expected correlation between death and progression is weak and we expect to 
have high values of HR1 (0.976), although the expected HR2 (effect over progression) may 
be mild (0.99), in half of the cases the inclusion of progression might be recommended. 
Most part of the investigators, in the scenario where they foresee a mild effect over 
patient’s progression would reject to include it as part of a clinical trial endpoint. We are in 
a scenario where we expect to find mild improvement from the experimental therapy 
against the control group, but we may find situations where this improvement is 
worthwhile the effort. 
4. In scenarios where the expected HR2 = 0.84, and we expect low correlation between death 
and progression, if HR1 > 0.73, in 100% of the cases it is recommended the use of the 
composite endpoint. At HR1=0.73, though, we find that in 77.8% of the cases we find that 
the composite endpoint as the most advisable, so we should test the ARE behavior in HR1 
values <0.73 to see if the percentage keeps decreasing. As the correlation increases, and as 
above highlighted, this relation disappears, and for medium correlation values the addition 
of the composite endpoint is only suggested when no real benefit is expected for HR1. 
What may even suggest to not using death as an endpoint in our trial. 
5. For P2 values > 0.16 and low correlation between endpoints, at the analyzed P1 values 
range, in > 66.7% of the cases the use of composite endpoint was recommended, while as 
the correlation increases the recommendation falls to around 30%. 
6. In terms of the (P1,HR1) clusters analyzed, we observed that those trials that fell under the 
(0.07,0.976), in 85.2% and 66.7% of the scenarios recommended the composite endpoint 
when correlation was low and medium respectively. 
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6.1.2. Advanced Breast Cancer data 
 
1. At the correlation levels this study was conducted, we can consider that the effects of the 
correlation can be negligible. We have already mentioned the limitations on this regard in 
our work, but from a clinical perspective, in advanced patients progression and death are 
correlated and often not very distant in time from each other. We tested for advanced 
breast cancer data correlation levels (ρ) of 0.45 and 0.75, and what we have seen is that 
the effect seen in stage 0 barely disappears. Under same conditions of HR1, HR2, P1 or P2, 
if we compare the percentage of scenarios where the ARE value recommends the use of 
composite endpoint between scenarios with moderate correlation and those with high, we 
observe that the difference between these percentages is never higher than 10%, being in 
most of the cases the same values.  
2. Only in cases where the expected HR2 is lower than the HR1, or HR2 values are ∼0.66, the 
use of composite endpoint is recommended in about 66% of the cases. Again, death and 
progression are linked in advanced stages of the disease, so only high improvements on 
progression may be considered to be added to death in a clinical trial. 
3. In line with the previous recommendation, only when HR2 is ≤ 0.8 and P2 value is >0.56, 
more than 65 % of the scenarios recommend the addition of progression to death. Even if 
the prognosis for a patient with advanced breast cancer is bad, observing improvements of 
more than 20% in terms of progression provide enough statistical benefit to recommend 
the use of the composite endpoint. 
4. Decisions based on P1 and P2 do not provide clear guidance on what is best, as the 
percentages of use or not of the composite endpoint are evenly distributed. 
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7. Limitations and future development of the statistical methodology 
 
The first limitation of this study is an advantage as well. The bibliographic research has been 
limited to papers published between 2009 and 2010. The direct impact of this is that the 
number of papers is reduced, and although the initial pull of papers was big, the final selection 
was a reduced sample of all this. At the same time this is a benefit for our data, as taking data 
from a wider time period may include studies with different standards of care that may had 
given us a less homogeneous data and one source of bias. 
As we already mentioned in section 3, the methodology used in our study assumes that the 
end of study censoring is the only non-informative one. However, clinical trials often have drop 
out patients due to other uncontrolled circumstances, i.e. withdrawal of patient’s consent, 
change of patient’s residence. In these cases the information provided by patients is censored, 
and although the trial team does all efforts to try to get the information they may not reach to 
get it. Therefore, this methodology should be tested as well assuming that there might be 
situations where apart form the end of study, we have non-informative censoring of data. 
With regards to the raw data ranges selection, some of the selected papers do not provide all 
the information needed, and therefore from some of the endpoints the value of probabilities 
and hazard ratios that have been estimated were not taken from a sample with the 
appropriate number of values from the literature. 
In terms of the number of points taken, and since the purpose of this study was to be as 
concrete as possible and to generate scenarios as similar to the reality as possible, we reduced 
each variable to 3 or 4 points, with even distribution among them. The results showed, though, 
that the percentage of scenarios where the ARE recommended the use of composite endpoint  
was changing sometimes from one point to the next from 0% to 100%, what would suggest 
that it would be worthwhile to consider points between the ones already selected to detect 
and better characterize the behavior of ARE for that variable. This would mean though the 
creation of more scenarios, which may generate a higher number of data combinations and 
therefore more computational power requested. 
Regarding future research that could follow this study, we could work to validate the results 
and the conclusions obtained in this work. We would need to come back to the papers found 
in the literature and check the primary endpoint chosen by the investigators and their p-
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values. We should be able to see if papers used the proper test for the clinical trial, and if the 
outcome matches with the ARE recommendation. 
The real benefit of the statistical methodology introduced by Gómez and Lagakos is not 
checking whether clinical trials that already published their results took the correct decision 
when they decided to use a composite endpoint in stead of a single one, but to prove that this 
methodology can be used when an investigator or a company wants to design a clinical trial. 
Using this methodology, a user friendly ARE calculator might be set up. Investigators would be 
supposed to introduce the expected values of the parameters they know or they expect, and 
the ARE results would recommend the most efficient endpoint. 
Once defined the most efficient endpoint, we would calculate the sample size according to 
that clinical trial endpoint, for which calculation we do not need any other information than 
the one needed for the ARE calculation. We would be able, then to ensure that the sample size 
obtained is the most efficient and optimal one.  
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Authors Title Date and Journal of publication 
Bramwell VH, et al. 
A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with 
early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12). 
Annals of Oncology 21: 283–290, 2010 
Sirohi B, et al. 
A randomized comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast 
cancer: the TRAFIC trial. 
Annals of Oncology 21: 1623–1629, 2010 
Blohmer JU, et al. 
Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic 
breast cancer: final results of a randomized phase III trial 
Annals of Oncology 21: 1430–1435, 2010 
Joensuu H, et al. 
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a 
randomized trial. 
Annals of Oncology 21: 968–973, 2010 
Eidtmann H, et al. 
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month 
results of the ZO-FAST Study 
Annals of Oncology 21: 2188–2194, 2010 
Frasci G, et al. 
Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer 
patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomized trial 9908 
Annals of Oncology 21: 707–716, 2010 
Seidman AD,et al. 
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the 
alternate single agent in metastatic breast cancer 
Annals of Oncology 22:1094-101, 2011 
Mavroudis D, et al. 
Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line 
treatment in women with advanced breast cancer 
Annals of Oncology 21: 48–54, 2010 
Canavese G,et al. 
Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically 
negative lymph nodes: results of randomized trial 
Annals of Oncology 20: 1001–1007, 2009 
Katsumata N, et al. 
Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line 
chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802) 
Annals of Oncology 20: 1210–1215, 2009 
Stopeck AT, et al. 
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast 
cancer: a randomized, double-blind study 
J Clin Oncol.  10;28(35):5132-9, 2010 
Moebus V,et al. 
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with 
conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study 
J Clin Oncol.  10;28(17):2874-80, 2010 
Sparano JA, et al. 
Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast 
cancer previously treated with an anthracycline and a taxane 
J Clin Oncol. Jul 10;28(20):3256-63,  2010 
Di Leo A, et al. 
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal 
women with estrogen receptor-positive advanced breast cancer 
J Clin Oncol.  20;28(30):4594-600, 2010 
Wardley AM, et al. 
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus 
docetaxel in HER2-positive metastatic breast cancer 
J Clin Oncol. 20;28(6):976-83. 2010 
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Blackwell KL, et al. 
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, 
trastuzumab-refractory metastatic breast cancer 
J Clin Oncol. 1;28(7):1124-30, 2010 
Martín M, et al. Adjuvant docetaxel for high-risk, node-negative breast cancer N Engl J Med. 2;363(23):2200-10, 2010 
Swain SM, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer N Engl J Med, 3;362(22):2053-65, 2010 
Hyman B. Muss, et al. Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer N Engl J Med 2009; 360:2055-2065, 2009 
Katsumata N, et al. 
Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line 
chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial  
Ann Oncol.  Jul;20(7):1210-5, 2009 
Gnant M, et al. 
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month 
follow-up from the ABCSG-12 randomized trial 
N Engl J Med 2009;360:679-91 
Joensuu H,et al. 
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as 
adjuvant treatments of breast cancer: final results of the FinHer Trial 
J Clin Oncol. 1;27(34):5685-92, 2009 
Gray R, et al. 
Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With 
Metastatic Breast Cancer 
J Clin Oncol. 20;27(30):4966-72, 2009 
Johnston S, et al. 
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone 
receptor-positive metastatic breast cancer 
J Clin Oncol. 2009 20;27(33):5538-46 
de Azambuja E, et al. 
Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy 
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Appendix 2 –Selected clinical trials data used 
 
ID phase stage N primary P1 P2 P3 HR1 HR2 HR3 p-v0 p-v1 p-v2 p-v3 
2 3 0 672 1 0,28 NA 0,36 0,78 0,77 NA NA 0,12 NA 0,056 
3 3 0 349 2 0,34 0,40 NA 0,78 0,84 NA NA 0,19 0,33 NA 
4 3 1 236 0 0,57 NA 0,73 0,663 NA 0,98 0,63 0,21 NA 0,38 
5 3 1 237 0 NA 0,74 NA 1,11 1,05 NA 0,31 0,6 0,72 NA 
6 NA 0 1064 0 NA NA 0,08 NA NA 0,59 NA NA NA 0,0314 
7 NA 1 200 2 0,41 0,56 NA NA NA NA NA 0,07 0,11 NA 
9 3 1 475 2 NA NA NA 1,031 1,101 NA NA 0,785 0,39 NA 
10 3 1 272 2 0,48 0,79 NA NA NA NA NA 0,744 0,735 NA 
13 NA 0 248 3 0,05 NA 0,09 0,95 1 NA NA 0,679 NA 0,715 
14 3 1 293 0 0,86 NA NA NA NA NA 0,13 0,09 NA NA 
15 3 1 2046 2 0,17 0,12 NA NA NA NA NA 0,49 0,93 NA 
16 3 0 1284 3 0,22 NA 0,36 0,76 NA 0,72 NA 0,029 NA 0 
18 3 1 1221 1 0,74 NA 0,50 0,9 NA 0,79 NA 0,231 NA 0,0005 
19 3 1 736 3 NA NA 0,86 0,84 NA 0,8 NA 0,091 NA 0,006 
27 2 1 222 0 0,66 NA NA NA 0,704 0,725 0,717 NA 0,033 0,0449 
28 3 1 296 3 0,48 NA 0,86 0,75 NA 0,73 NA 0,106 NA 0,008 
29 3 0 1060 3 0,07 NA 0,18 0,76 NA 0.68 NA 0,29 NA 0,01 
30 3 0 3506 1 0,16 NA 0,27 0,83 NA 0,8 NA 0,03 NA 0,001 
31 NA NA 633 3 0,07 NA 0,11 1,85 NA 2,09 NA 0,02 NA 0,001 
32 3 1 290 0 0,80 NA NA NA NA NA 0,09 0,13 NA NA 
33 NA 0 1803 3 0,03 0,09 0,12 0,6 0,65 0,64 NA 0,11 0,01 0,01 
34 3 0 1009 3 0,11 NA 0,48 0,8 NA 0,66 NA 0,086 NA 0,01 
35 3 1 722 3 NA NA 0,52 NA NA 0,483 NA NA NA 0 
37 3 1 219 3 NA NA 0,98 0,74 NA 0,71 NA 0,113 NA 0,019 
Appendix 2 –Selected clinical trials data used (cont) 
Master’s Degree Thesis      MSc in Statistics and Operations Research 
 84 
 
ID phase stage N primary P1 P2 P3 HR1 HR2 HR3 p-v0 p-v1 p-v2 p-v3 
38 3 0 522 3 0,37 NA NA 0,85 NA 0,75 NA 0,26 NA 0,02 
40 3 1 305 3 0,76 NA 0,93 NA NA 1,2 NA 0,983 NA 0,121 
43 NA 0 264 3 0,21 NA 0,27 0,63 NA 0,36 NA 0,11 NA 0,00071 
44 2 1 148 0 NA NA 0,45 NA NA 0,495 NA NA NA 0,0065 
45 NA 0 528 3 0,07 NA 0,26 1,27 NA 0,86 NA NA NA 0,41 
46 3 1 207 3 0,62 0,88 0,95 NA NA 0,63 NA 0,325 0,0007 0,0016 
53 3 0 3094 3 0,09 0,08 0,16 1,13 1,22 1,05 NA NA NA NA 
54 NA 0 1234 2 0,21 0,07 NA NA NA NA NA 0,79 0,01 NA 
 
ID: order number given to each selected trial. 
Phase: clinical trial development phase. 
Stage: 0 for early disease and 1 for advanced breast cancer. 
Primary: coding if the primary endpoint was 1 = death; 2 = progression; 3 = composite endpoint. 
P: probability of the event in the control group depending on the type of endpoint: 1 = death; 2 = progression; 3 = composite endpoint. 
HR: hazard ratio in the control group depending on the type of error coded as above 
p-v : p-value of each endpoint, coded as above adding code 0, where primary endpoint was not a survival one. 
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Appendix 3 – Clinical Trials selected summary 
 
































C. Clinical Trials Development Phase 
Clincal Trials Development Phase
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 levels = c("P","S"), 
 labels = c("Primary", "Secondary"))  
 
ce$Phase<-factor(ce$Phase, 
 levels = c(2,3), 
 labels = c("fase II", "fase III"))  
ce$Stage<-factor(ce$Stage, 
 levels = c("0","1"), 











stage',ylab="P0 distribution", lwd=2) 
title("P0 distribution per Disease Stage") 
 
boxplot(ce$P0~ce$Phase,xlab='Trial 
phase',ylab="P0 distribution", lwd=2) 
title("P0 distribution per Trial phase") 
 
boxplot(ce$HR~ce$Stage,xlab='Disease 
stage',ylab="HR distribution", lwd=2) 
title("HR distribution per Disease Stage") 
 
boxplot(ce$HR~ce$Phase,xlab='Trial 
phase',ylab="HR distribution", lwd=2) 




#Rmatrix2 data.  
#differentiates what kind of primary 








 levels = c(2,3), 
 labels = c("fase II", "fase III"))  
cE2$stage<-factor(cE2$stage, 
 levels = c(0,1), 
 labels = c("Early", "Advanced"))  
cE2$primary<-factor(cE2$primary, 
 levels = c(0,1,2,3), 
 labels = c("ORR/TTF", "Death", 













xlim=c(0,35), ylim=c(0,1), lwd=1, ylab="P1 
distr", xlab=" Selected clinical trials") 





 title("Death primary endpoint") 
 
plot(cE2$P2, col=c(cE2$stage), 
xlim=c(0,35), ylim=c(0,1), lwd=1,ylab="P2 
distr",xlab=" Selected clinical trials") 





 title("Progression as primary 
endpoint") 
 
plot(cE2$P03, col=c(cE2$stage), lwd=1, 
xlim=c(0,35), ylim=c(0,1), ylab="P03 
distr", xlab=" Selected clinical trials") 














# complete dataset 
plot(ce$P0~ce$HR,col=1, lwd=2, xlab="HR 
values", ylab="P0 values") 
 title("P0 and HR distr - Pooled 
data") 
 





plot(ce$P0~ce$HR,col=1, lwd=2, xlab="HR 
values", ylab="P0 values", 
data=(ce$Stage=0)) 
 title("P0 and HR distr - Disease 
Stage 0") 
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plot(ce$P0~ce$HR,col=2, lwd=2, xlab="HR 
values", ylab="P0 values", 
data=(ce$Stage=0)) 




## P and HR correlation per stage and 









#stage 0 - P1_HR1 
plot(phr0$P1~phr0$HR1,col=1, 
ylim=c(0,1),lwd=2, xlab="HR1 values", 
ylab="P1 values", data=(phr0)) 
 title("P1 and HR1 distr - Disease 
Stage 0") 
#stage 1 - P1_HR1 
plot(pHR1$P1~pHR1$HR1,col=1, 
ylim=c(0,1),lwd=2, xlab="HR1 values", 
ylab="P1 values", data=(pHR1)) 
 title("P1 and HR1 distr - Disease 
Stage 1") 
 
#stage 0 - P2_HR2 
plot(phr0$P2~phr0$HR2,col=1, ylim=c(0,1), 
lwd=2, xlab="HR2 values", ylab="P2 
values", data=(phr0)) 
 title("P2 and HR2 distr - Disease 
Stage 0") 
#stage 1 - P2_HR2 
plot(pHR1$P2~pHR1$HR2,col=1, 
ylim=c(0,1),lwd=2, xlab="HR2 values", 
ylab="P2 values", data=(pHR1)) 














#stage 0 - P1_HR1 
plot(phr0b$P1~phr0b$HR1,col=1, lwd=2, 
xlab="HR1 values", ylab="P1 values", 
data=(phr0b)) 
 title("P1 and HR1 distr - Disease 
Stage 0") 
#stage 1 - P1_HR1 
plot(pHR1b$P1~pHR1b$HR1,col=1, lwd=2, 
xlab="HR1 values", ylab="P1 values", 
data=(pHR1b)) 
 title("P1 and HR1 distr - Disease 
Stage 1") 
 
#stage 0 - P2_HR2 
plot(phr0b$P2~phr0b$HR2,col=1, lwd=2, 
xlab="HR2 values", ylab="P2 values", 
data=(phr0b)) 
 title("P2 and HR2 distr - Disease 
Stage 0") 
#stage 1 - P2_HR2 
plot(pHR1b$P2~pHR1b$HR2,col=1, lwd=2, 
xlab="HR2 values", ylab="P2 values", 
data=(pHR1b)) 





 as we are only using HRs until 0.99, this 
data has all HR>1 turned into 0.99 









s0P1HR1b<- na.omit(s0P1HR1b) # listwise 
deletion of missing 
 
## K-Means Cluster Analysis 
 
# 2 cluster solution 
fit1 <- kmeans(s0P1HR1b, 2) 
 # get cluster means  
aggregate(s0P1HR1b,by=list(fit1$cluster),F
UN=mean) 
 # append cluster assignment 
s0P1HR1c1 <- data.frame(s0P1HR1b, 
fit1$cluster) 
 
# 3 cluster solution 
fit2 <- kmeans(s0P1HR1b, 3)  
 # get cluster means  
aggregate(s0P1HR1b,by=list(fit2$cluster),F
UN=mean) 
 # append cluster assignment 






color=TRUE, shade=TRUE,  
   labels=2, lines=0, main="d.stage0 P1 
HR1 - 2 clusters") 
clusplot(s0P1HR1c2, fit2$cluster, 
color=TRUE, shade=TRUE,  
   labels=2, lines=0, main="d.stage0 P1 
HR1 - 3 clusters") 
 
# comparing 2 cluster solutions 
 library(fpc) 







### DATA CLUSTERING  
################################## 
 
# seen P0 and HR distribution, clustering 






s0P1HR1<- na.omit(s0P1HR1) # listwise 






## K-Means Cluster Analysis 
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# 2 cluster solution 
fit1 <- kmeans(s0P1HR1, 2) 
 # get cluster means  
aggregate(s0P1HR1,by=list(fit1$cluster),FU
N=mean) 
 # append cluster assignment 
s0P1HR1c1 <- data.frame(s0P1HR1, 
fit1$cluster) 
 
# 3 cluster solution 
fit2 <- kmeans(s0P1HR1, 3)  
 # get cluster means  
aggregate(s0P1HR1,by=list(fit2$cluster),FU
N=mean) 
 # append cluster assignment 






color=TRUE, shade=TRUE,  
   labels=2, lines=0, main="d.stage0 P1 
HR1 - 2 clusters") 
clusplot(s0P1HR1c2, fit2$cluster, 
color=TRUE, shade=TRUE,  
   labels=2, lines=0, main="d.stage0 P1 
HR1 - 3 clusters") 
 
# comparing 2 cluster solutions 
 library(fpc) 




## WE CHOOSE THE 3 CLUSTERS OPTION 
 
########################################## 
### ARE CALCULATION FOR STAGE 0  
### using Moisés Gómez Mateu R programming 
########################################## 
 
setwd("H:\\MEIO\\TFM - composite 











#values for stage 0 from the bibl. 
research 
beta1V <- c(0.5,1,2) # constant risk or 
increasing 
beta2V <- c(0.5,1,2) 












for (beta1X in 1:length(beta1V)){ 
for (beta2X in 1:length(beta2V)){ 
for (P1X in 1:length(P1V)){ 
for (P2X in 1:length(P2V)){ 
for (HR1X in 1:length(HR1V)){ 
for (HR2X in 1:length(HR2V)){ 























# WE SAVE THE DATA IN A .CSV2 FILE 












= TRUE, sep = ";", quote="\"", dec=",") 
 
dataset2<-dataset2[,2:8] # only if it 






## INTENTO FER EL CLUSTER AMB LES 
INSTRUCCIONS DEL MOISES DE MÉS ABAIX 
 
dataset2<-subset(dataset2,( 
((P1== 0.07 )&(HR1== 0.976 ))| 
((P1== 0.33 )&(HR1== 0.803 ))| 
((P1== 0.133 )&(HR1== 0.730 )))) 
 
# en principi només ha creuat les P1 y HR1 
sel.leccionades i crec que surt bé 
 
View(dataset2) 
dataset2<-dataset2[,2:8] # only if it 
creates an extra column 
 
##########################################














#for (i in 3580:3590) { 
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for (i in 1:nrow(dataset2)) { 
 
# IMPUTING VALUES TO THE PARAMETERS 
 
beta1 <- dataset2[i,1] 
beta2 <- dataset2[i,2] 
P1 <- dataset2[i,3] 
P2 <- dataset2[i,4] 
HR1 <-dataset2[i,5] 
HR2 <- dataset2[i,6] 
rho <- dataset2[i,7] 
 




# Functions: f, F  
########################################## 
# Description: It computes Theta from the 
values of Rho 
#  
# Arguments: 
# t   Time to event Random 
variable. 
# theta  We calculate theta from the 
values of Rho 
# Rho   Spearman's 
coefficient that we set 
########################################## 
 
f <- function(t,theta) { 
  num <- t*theta-2*t^2 
  den <- theta*(exp(t)-1) 
  return(num/den) 
} 
 
F <- function(theta,rho) { 
  inte <- integrate(f, lower=0, 
upper=theta, theta=theta, 
subdivisions=1000)$value 
  return(1- 12*inte/theta^2 - rho) 
} 
 
limits <- c(0.00001,1000)  




####### ASSESSMENT OF THE SCALE PARAMETER 
VALUES b10, b11, b20, b21 
 
b10 <- 1/((-log(1-P1))^(1/(beta1))) 
b11 <- b10/HR1^(1/beta1) 
# b20 <- 1/(-log(1-P2))^(1/beta2)  
 
########################################## 
# Function: Fb20  
###################################### 
# Description: It computes b20 values 










sapply(y, function(y) { 
integrate(function(x) ( (theta*(1-
exp(-theta))*exp(-theta*(x+y)))/ (exp(-
theta)+  exp(-theta*(x+y))  - exp(-
theta*x)-exp(-theta*y))^2  
   )    , lower=0, 
upper=exp( -(  (((-log(y))^(1/beta2)) 
* b20) /b10)^beta1 ) )$value 
}) 








limits <- c(0.00001,100000)  
b20 <- uniroot(Fb20, 
interval=limits,P2=P2)$root   
#b20 
 




# Function: numerador  
####################################### 
# Description: It computes the numerador 











  fT10 <- (beta1/b10) * ( (t/b10)^(beta1-
1) ) * (exp(-(t/b10)^beta1)) 
  fT11 <- (beta1/b11) * ( (t/b11)^(beta1-
1) ) * (exp(-(t/b11)^beta1)) 
  fT20 <- (beta2/b20) * ( (t/b20)^(beta2-
1) ) * (exp(-(t/b20)^beta2)) 
  fT21 <- (beta2/b21) * ( (t/b21)^(beta2-
1) ) * (exp(-(t/b21)^beta2)) 
  ST10 <- exp(-(t/b10)^beta1) 
  ST11 <- exp(-(t/b11)^beta1) 
  ST20 <- exp(-(t/b20)^beta2) 
  ST21 <- exp(-(t/b21)^beta2) 
  Sstar0 <- (-log(1+(exp(-theta*ST10)-
1)*(exp(-theta*ST20)-1)/(exp(-theta)-
1))/theta) 





  Lstar0 <- (fstar0/Sstar0) 
  Sstar1 <- (-log(1+(exp(-theta*ST11)-
1)*(exp(-theta*ST21)-1)/(exp(-theta)-
1))/theta) 





  Lstar1 <- (fstar1/Sstar1) 
  HRstar <- (Lstar1/Lstar0) 
  logHRstar <- log(HRstar) 
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# fstar1,Lstar1,HRstar,logHRstar  









 fstar1,Lstar1,HRstar,logHRstar  





integrate(numerador, lower = 0, upper = 1, 























ST10_1 <- exp(-(1/b10)^beta1) 




ST10_1 <- exp(-(1/b10)^beta1) 
 
denominador <- (  (log(HR1))^2  )* (1-
Sstar0_1) * (1-ST10_1) 
 
AREstarT <- (numerador2/denominador) 
 
 
# IF THE VALUE THE NUMERATOR IS NOT 
COMPUTED, THEN WE ASSIGN A MISSING IN THE 
ARE VALUE 
 
if(numerador1$message!="OK") {AREstarT <- 
NA} 





# END OF ITERATIONS 
########################################## 
 






# SAVING DATA IN A .CSV2 FILE (SEPARATED 





# READING THE DATASET 
 
dataset2<-read.csv2("stage_0_ARE_c.csv2", 






### ARE CALCULATION FOR STAGE 1  
### using Moisés Gómez Mateu R programming 
 
setwd("H:\\MEIO\\TFM - composite 






# WE SET THE PARAMETER VALUES IN A DATASET 
# 
# Note: for a large number of 
combinations, it is better to compute it 
step by step. 
# That is, with the larger vector, compute 
the dataset for each value separatelly. It 
is 







#values for stage 0 from the bibl. 
research 
beta1V <- c(1,2) 
beta2V <- c(1,2) 











for (beta1X in 1:length(beta1V)){ 
for (beta2X in 1:length(beta2V)){ 
for (P1X in 1:length(P1V)){ 
for (P2X in 1:length(P2V)){ 
for (HR1X in 1:length(HR1V)){ 
for (HR2X in 1:length(HR2V)){ 

















 V5 ='HR1', V6 = 'HR2',    V7='rho')) 
 
View(dataset) 




# WE SAVE THE DATA IN A .CSV2 FILE 











read.csv2("stage_1_dataset.csv2", header = 
TRUE, sep = ";", quote="\"", dec=",") 
 
dataset2<-dataset2[,2:8] # only if it 




















#for (i in 3580:3590) { 
 
for (i in 1:nrow(dataset2)) { 
 
# IMPUTING VALUES TO THE PARAMETERS 
 
beta1 <- dataset2[i,1] 
beta2 <- dataset2[i,2] 
P1 <- dataset2[i,3] 
P2 <- dataset2[i,4] 
HR1 <-dataset2[i,5] 
HR2 <- dataset2[i,6] 
rho <- dataset2[i,7] 
 




# Functions: f, F  
###################################### 
# Descricption: It computes Theta from the 
values of Rho 
#  
# Arguments: 
# t   Time to event Random 
variable. 
# theta  We calculate theta from the 
values of Rho 
# Rho   Spearman's 
coefficient that we set 
###################################### 
 
f <- function(t,theta) { 
  num <- t*theta-2*t^2 
  den <- theta*(exp(t)-1) 
  return(num/den) 
} 
 
F <- function(theta,rho) { 
  inte <- integrate(f, lower=0, 
upper=theta, theta=theta, 
subdivisions=1000)$value 
  return(1- 12*inte/theta^2 - rho) 
} 
 
limits <- c(0.00001,1000)  




####### ASSESSMENT OF THE SCALE PARAMETER 
VALUES b10, b11, b20, b21 
 
b10 <- 1/((-log(1-P1))^(1/(beta1))) 
b11 <- b10/HR1^(1/beta1) 
# b20 <- 1/(-log(1-P2))^(1/beta2)  
 
########################################## 
# Function: Fb20  
# Description: It computes b20 values 
(What is different from the CASE 1) 
# Arguments: 
# b20 






sapply(y, function(y) { 
integrate(function(x) ( (theta*(1-
exp(-theta))*exp(-theta*(x+y)))/ (exp(-
theta)+  exp(-theta*(x+y))  - exp(-
theta*x)-exp(-theta*y))^2  
   )    , lower=0, 
upper=exp( -(  (((-log(y))^(1/beta2)) 
* b20) /b10)^beta1 ) )$value 
}) 








limits <- c(0.00001,100000)  
b20 <- uniroot(Fb20, 
interval=limits,P2=P2)$root   
#b20 
 
b21 <- b20/HR2^(1/beta2) 
 
 
# Function: numerador  
###################################### 
# Description: It computes the numerador 











  fT10 <- (beta1/b10) * ( (t/b10)^(beta1-
1) ) * (exp(-(t/b10)^beta1)) 
  fT11 <- (beta1/b11) * ( (t/b11)^(beta1-
1) ) * (exp(-(t/b11)^beta1)) 
  fT20 <- (beta2/b20) * ( (t/b20)^(beta2-
1) ) * (exp(-(t/b20)^beta2)) 
  fT21 <- (beta2/b21) * ( (t/b21)^(beta2-
1) ) * (exp(-(t/b21)^beta2)) 
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  ST10 <- exp(-(t/b10)^beta1) 
  ST11 <- exp(-(t/b11)^beta1) 
  ST20 <- exp(-(t/b20)^beta2) 
  ST21 <- exp(-(t/b21)^beta2) 
  Sstar0 <- (-log(1+(exp(-theta*ST10)-
1)*(exp(-theta*ST20)-1)/(exp(-theta)-
1))/theta) 





  Lstar0 <- (fstar0/Sstar0) 
  Sstar1 <- (-log(1+(exp(-theta*ST11)-
1)*(exp(-theta*ST21)-1)/(exp(-theta)-
1))/theta) 





  Lstar1 <- (fstar1/Sstar1) 
  HRstar <- (Lstar1/Lstar0) 
  logHRstar <- log(HRstar) 
  return(logHRstar*fstar0) 
} 
 
# WITH BETAS = 0.5, THERE ARE SOME CASES 
WHERE THE INTEGRAL DIVERGES AND STOPS  
# THE LOOP. HENCE, I ADD "stop.on.error = 
FALSE" INSTRUCTION. 
 
# AND THERE ARE ALSO SOME COMBINATIONS 
WHERE THE FUNCTION funcion() DOESN'T  
# HAVE VALUES FOR CERTAIN VALUES OF T (EX. 
T>0.9). HENCE, WE FIRST EVALUATE THE  
# INTEGRATE BEFORE CONTINUING. IF THERE IS 
ANY PROBLEM, THEN R ASSIGNS A MISSING 
# TO THE ARE VALUE AND IT CONTINUES WITH 








# fstar1,Lstar1,HRstar,logHRstar  









 fstar1,Lstar1,HRstar,logHRstar  





integrate(numerador, lower = 0, upper = 1, 




{dataset2[i,8] <- NA ; next(i)} 
 
##########################################
# Integrating using sums 
#h<-seq(0.0001,1,by=0.0001) 
#temp<-h*0 













ST10_1 <- exp(-(1/b10)^beta1) 




ST10_1 <- exp(-(1/b10)^beta1) 
 
denominador <- (  (log(HR1))^2  )* (1-
Sstar0_1) * (1-ST10_1) 
 
AREstarT <- (numerador2/denominador) 
 
# IF THE VALUE THE NUMERATOR IS NOT 
COMPUTED, THEN WE ASSIGN A MISSING IN THE 
ARE VALUE 
 
if(numerador1$message!="OK") {AREstarT <- 
NA} 




# END OF ITERATIONS 
########################################## 
 






# SAVING DATA IN A .CSV2 FILE (SEPARATED 






# READING THE DATASET 
dataset2<-read.csv2("stage_1_ARE.csv2", 
header = TRUE, sep = ";", quote="\"", 
dec=",") 
View(dataset2) 
dataset2<-dataset2[,2:9] 
#####################################
 
